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Background: Management of bone and joint infection commonly includes 4–6 weeks of intravenous (IV)
antibiotics, but there is little evidence to suggest that oral (PO) therapy results in worse outcomes.
Objective: To determine whether or not PO antibiotics are non-inferior to IV antibiotics in treating bone
and joint infection.
Design: Parallel-group, randomised (1 : 1), open-label, non-inferiority trial. The non-inferiority margin
was 7.5%.
Setting: Twenty-six NHS hospitals.
Participants: Adults with a clinical diagnosis of bone, joint or orthopaedic metalware-associated infection
who would ordinarily receive at least 6 weeks of antibiotics, and who had received ≤ 7 days of IV therapy
from definitive surgery (or start of planned curative treatment in patients managed non-operatively).
Interventions: Participants were centrally computer-randomised to PO or IV antibiotics to complete the
first 6 weeks of therapy. Follow-on PO therapy was permitted in either arm.
Main outcome measure: The primary outcome was the proportion of participants experiencing treatment
failure within 1 year. An associated cost-effectiveness evaluation assessed health resource use and
quality-of-life data.
Results: Out of 1054 participants (527 in each arm), end-point data were available for 1015 (96.30%)
participants. Treatment failure was identified in 141 out of 1015 (13.89%) participants: 74 out of
506 (14.62%) and 67 out of 509 (13.16%) of those participants randomised to IV and PO therapy,
respectively. In the intention-to-treat analysis, using multiple imputation to include all participants, the
imputed risk difference between PO and IV therapy for definitive treatment failure was –1.38% (90%
confidence interval –4.94% to 2.19%), thus meeting the non-inferiority criterion. A complete-case analysis,
a per-protocol analysis and sensitivity analyses for missing data each confirmed this result. With the
exception of IV catheter complications [49/523 (9.37%) in the IV arm vs. 5/523 (0.96%) in the PO arm)],
there was no significant difference between the two arms in the incidence of serious adverse events. PO
therapy was highly cost-effective, yielding a saving of £2740 per patient without any significant difference
in quality-adjusted life-years between the two arms of the trial.
Limitations: The OVIVA (Oral Versus IntraVenous Antibiotics) trial was an open-label trial, but bias was
limited by assessing all potential end points by a blinded adjudication committee. The population was
heterogenous, which facilitated generalisability but limited the statistical power of subgroup analyses.
Participants were only followed up for 1 year so differences in late recurrence cannot be excluded.
Conclusions: PO antibiotic therapy is non-inferior to IV therapy when used during the first 6 weeks in
the treatment for bone and joint infection, as assessed by definitive treatment failure within 1 year of
randomisation. These findings challenge the current standard of care and provide an opportunity to realise
significant benefits for patients, antimicrobial stewardship and the health economy.
Future work: Further work is required to define the optimal total duration of therapy for bone and joint
infection in the context of specific surgical interventions. Currently, wide variation in clinical practice
suggests significant redundancy that likely contributes to the excess and unnecessary use of antibiotics.
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Trial registration: Current Controlled Trials ISRCTN91566927.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 38.
See the NIHR Journals Library website for further project information.
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Plain English summary
T reatment of bone and joint infection usually requires a long course of antibiotics. Doctors usually givethese by injection through a vein (intravenously) for the first 4–6 weeks, rather than by mouth (orally).
Although intravenous (IV) administration is more expensive and less convenient for patients, most doctors
believe that it is more effective. However, there is little evidence to support this. The OVIVA (Oral Versus
IntraVenous Antibiotics) trial set out to challenge this assumption.
A total of 1054 patients from 26 UK hospitals were randomly allocated to receive the first 6 weeks of
antibiotic therapy either intravenously or orally. Irrespective of the route of administration, the choice of
antibiotic was left to an infection specialist so as to ensure that the most appropriate antibiotics were
given. Patients were followed up for 1 year.
Thirty-nine participants were lost to follow-up. Among the remaining 1015 participants, treatment failure
occurred in 14.6% of those treated intravenously and 13.2% of those treated with PO antibiotics. This
difference could easily have occurred by chance. Even if it was not by chance, the difference does not
suggest that PO therapy is associated with worse outcomes than IV therapy and is too small to conclude
that PO therapy is better than IV therapy.
Participants in the IV group stayed in hospital longer and 10% of them had complications related to the
IV line used for administering the antibiotics. In addition, their treatment was, overall, more expensive.
We conclude that PO antibiotic therapy has no disadvantages for the early management of bone and joint
infection. It is also cheaper and associated with fewer complications.
DOI: 10.3310/hta23380 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 38
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Scarborough et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi

Scientific summary
Background
Bone and joint infection in adults causes considerable morbidity. Treatment costs are estimated at
£20,000–40,000 per patient. The current standard of care in most UK centres includes a prolonged course
(i.e. 4–6 weeks) of intravenous (IV) antibiotics during the early treatment phase, although there is no
evidence that PO antibiotic therapy results in worse outcomes.
Objectives
The primary objective of the OVIVA (Oral Versus IntraVenous Antibiotics) trial was to determine whether or
not oral (PO) antibiotic therapy is non-inferior to IV therapy when given for the first 6 weeks of treatment
for bone and joint infection, as judged by the proportion of patients experiencing definite treatment failure
during 1 year of follow-up.
Secondary objectives included assessment of:
1. serious adverse events (SAEs), including death (i.e. all cause) according to treatment allocation
2. IV catheter line complications (i.e. infection, thrombosis or other events requiring early removal of
the line)
3. Clostridium difficile-associated diarrhoea
4. ‘probable’ and ‘possible’ treatment failure as composites with definitive treatment failure
5. early termination of the planned 6-week period of PO or IV antibiotics
6. resource allocation using (1) length of hospital stay, (2) outpatient visits and (3) antibiotic costs
7. quality of life, as evaluated by EuroQol-5 Dimensions questionnaire
8. Oxford Hip and Knee Scores (when infection involved the hip or knee)
9. patient adherence to treatment, as indicated by a Medication Event Monitoring System (MEMS) in a
subset of participants.
Methods
The trial was a multicentre, open-label, parallel-group, randomised (1 : 1), non-inferiority study. The primary
end point was definite treatment failure within 1 year. Eligible patients had anticipated life expectancy of
> 1 year, had a bone and joint infection for which at least 6 weeks of antibiotic therapy was considered
necessary and had received ≤ 7 days of IV antibiotic therapy following surgery (or from the start date
of planned curative therapy if there was no planned surgical intervention). Exclusion criteria were recent
Staphylococcus aureus bacteraemia, bacterial endocarditis or other infection mandating a prolonged
course of IV antibiotic therapy. Data were collected manually from care records, direct patient contact
and questionnaires prior to entry onto a centralised database (OpenClinica Enterprise version 3.4, 2014;
Waltham, MA, USA). The occurrence of definitive treatment failure was adjudicated by a blinded end-point
committee that reviewed relevant clinical records, redacted for indicators of treatment allocation and
patient identifiers.
Data were analysed using Stata® (version 14SE, StataCorp LP, College Station, TX, USA). The non-inferiority
margin was set at 7.5% [i.e. an absolute upper two-sided 90% confidence interval (CI) around the
unadjusted difference between PO and IV therapy of ≤ 7.5% was considered non-inferior].
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Results
A total of 1054 participants from 26 UK centres (including 228 from a single-site internal pilot study)
were randomised. Participants were evenly matched between the two arms of the trial for age, clinical
presentation, comorbidities, site and type of surgery, organism and histopathological diagnosis. Primary
end-point data were available for 1015 (96%) participants.
Definitive treatment failures were observed in 74 out of 527 (14.04%) participants in the IV arm and
67 out of 527 (12.71%) participants in the PO arm. A total of 432 (81.97%) and 442 (83.87%)
participants in the IV and PO arms, respectively, did not experience definitive treatment failures over the
1-year follow-up. Data on treatment failures were missing for 21 (3.98%) participants in the IV arm and
18 (3.42%) participants in the PO arm.
In an intention-to-treat analysis, using multiple imputation to include all randomised participants,
the imputed risk difference (PO – IV) for definitive treatment failure was estimated to be –1.38%
(90% CI –4.94% to 2.19%).
In a complete-case analysis, which included only those participants with primary end-point data at 1-year
follow-up, 74 out of 506 (14.62%) and 67 out of 509 (13.16%) participants in the IV and PO arms of the
trial, respectively, suffered a definitive treatment failure, representing a risk difference (PO – IV) of –1.46%
(90% CI –5.03% to 2.11%).
A per-protocol analysis, which included 909 patients who followed their allocated treatment strategy for at
least 4 weeks, showed definitive treatment failure in 69 out of 443 (15.58%) participants in the IV arm
and 61 out of 466 (13.09%) in the PO arm of the trial, representing a risk difference of –2.49% (90% CI
–6.31% to 1.34%).
All end-point analyses, as well as sensitivity analyses to investigate the potential impact of missing data,
were consistent in showing that the non-inferiority criteria were met.
Time to event modelling showed no difference in the time to definitive treatment failure between
the arms.
Prespecified subgroup analyses according to recruiting centre, pathogen and surgical management
(e.g. retention or removal of metalware) showed no significant difference in rate of definitive failure
between the two arms of the trial.
With the exception of line complications [49/523 (9.37%) in the IV arm vs. 5/523 (0.96%) in the PO arm],
there was no significant difference between the two arms of the trial in the incidence of SAEs, including death.
Participants randomised to IV therapy were hospitalised for longer than those randomised to PO therapy,
with a median (interquartile range) inpatient stay of 14 (11–21) days and 11 (8–20) days, respectively.
Patients randomised to IV therapy had an unadjusted excess treatment cost of £2727 (95% CI £1437 to
£3980) through to 1 year of follow-up.
Implications
1. Clinical outcome. The OVIVA trial demonstrates no clinical advantage of using prolonged IV therapy
compared with PO therapy in the early treatment of bone and joint infections requiring ≥ 6 weeks of
antibiotic therapy. The findings directly challenge a widely held view that the management of bone and
joint infection mandates a prolonged course of IV antibiotic therapy. This dogma was most notably
published as a specialist opinion in 1970, and since then it had been perpetuated through several
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iterations of guidelines, protocols and textbooks. A number of smaller studies investigating the
effectiveness of PO antibiotic therapy in osteomyelitis, including a meta-analysis involving 180 patients,
have suggested similar results but none was large enough to influence management. We believe that
the findings of the OVIVA study provide sufficiently robust evidence to inform a widespread change in
clinical practice.
2. Safety. Use of PO antibiotic therapy mitigates the risks associated with long-term IV access. In our trial,
around 10% of participants randomised to IV therapy developed complications directly related to the
use of IV lines.
3. Cost. In addition to the clinical findings, the results demonstrate that PO antibiotic therapy provides a
significant cost benefit and cost-effectiveness advantage over IV therapy, without additional risk of
adverse events. Assuming a total of 9000 bone and joint infections in adults are managed in UK
secondary care per year, routine use of PO as opposed to IV therapy could save the NHS around
£25M per year.
4. Patient pathway. Compared with IV therapy, PO antibiotics allow for earlier discharge from hospital.
This is of considerable advantage to patients and the NHS. It provides patient satisfaction, contributes
to the cost savings, optimises inpatient flow and limits the risks of health-care associated infections.
Although not formally assessed during the study, our experience suggests that use of PO therapy is
widely perceived as more convenient for patients. Most patients on prolonged IV therapy require
regular attendance of health-care providers and often are restricted in their social and professional
activities by the IV access device.
5. Antibiotic stewardship. The current availability of a wide range of effective PO antibiotics allows
clinicians to select the most appropriate, narrow-spectrum agent. This directly supports a national
objective of protecting the most valuable IV antibiotic agents against emergence of resistance by
minimising the use of unnecessarily broad-spectrum IV antibiotics.
Conclusion
Oral antibiotics are a safe, effective and convenient alternative to IV therapy in the early management of
serious bone and joint infection. Translation of these findings into routine clinical practice is likely to
benefit patients and provides an opportunity for substantial cost savings to the NHS.
Future research
1. Duration of therapy. To further support patient safety, cost improvement and antimicrobial stewardship,
additional work to define the optimal total duration of antibiotic therapy in bone and joint infection is
necessary. Currently, there is considerable variation between centres and between clinicians, which
suggests that there may be significant redundancy in antibiotic use. This almost certainly contributes to
the risk of emerging resistance to antimicrobials, an issue that is high on the agenda of the Department
of Health and Social Care and the medical community globally.
2. Antibiotic choice and dose. Effective antibiotic therapy requires the presence of therapeutic drug levels
at the site of the infected tissue. This depends on both bioavailability and tissue penetration. Optimising
antibiotic choice will require a programme of work that may include techniques such as microdialysis of
tissue fluid at the site of deep surgical infection.
Trial registration
This trial is registered as ISRCTN91566927.
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Chapter 1 Introduction
Some of the material in this chapter has previously been published in our description of the trial,reproduced from Li et al.1 This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Scientific background
Infections involving bones and joints are increasingly common. In the NHS in the UK, approximately
250,000 orthopaedic operations are performed annually, including 160,000 hip and knee replacements.2
Around 1% of these are reported to have been complicated by postoperative infection.3 In addition, there
are around 5000 diabetic foot infections with associated osteomyelitis and a smaller number of infections
of the axial skeleton. Treatment costs are estimated to be between £20,000 and £40,000 per patient.4–6
Many consider a prolonged course (4–6 weeks) of intravenous (IV) antibiotics to be the ‘gold standard’
during the early phase of treatment for bone and joint infections.7–9 However, such practice derives from
an era prior to properly embedded pharmacokinetic principles, during which a widely held view was
established that IV therapy is ‘stronger’ than PO therapy. As a result, IV antibiotic therapy is often preferred
to oral (PO) therapy and has become an accepted standard of care even for many non-acute infections.
The evidence base supporting this practice is, however, limited and there is a growing body of literature
from randomised controlled trials (RCTs) and pharmacokinetic studies that suggest that an early switch
to PO antibiotics is as effective as continued IV antibiotics. These studies have included patients with
pneumonia,10 urinary tract infections,11 low-risk neutropenic sepsis,12 skin and soft tissue infections13 and
endocarditis caused by Staphylococcus aureus.14 There are no large RCTs of PO versus IV antibiotics for bone
and joint infection but, provided that agents are carefully chosen with respect to bioavailability and tissue
penetration, there is no biologically plausible reason to believe that bone and joint infections should be any
different. A Cochrane review of five small trials involving a total 180 participants with bone or joint infection
showed no benefit of IV as compared with PO therapy.14,15 The largest single trial in this meta-analysis
comprised 59 patients and the authors concluded that there is currently insufficient evidence to inform a
widespread change in practice. Subsequent to this meta-analysis, a further trial involving 42 patients with
S. aureus osteomyelitis, who were randomised to either IV cloxacillin or PO combination therapy with
co-trimoxazole and rifampicin, showed similar results.16 Observational studies have reported high success
rates for prosthetic joint infection managed by two-stage revision and a shortened course of IV antibiotics or
use of antibiotic cement spacers,17,18 but observational comparisons are prone to confounding by indication
whereby, for example, only those patients with a better underlying prognosis are switched early to
PO antibiotics.
Prolonged IV antibiotic therapy mandates placement of an IV vascular access device, which carries a risk
of complications such as catheter-related infection and thromboembolic disease.6,19 PO antibiotic therapy
mitigates such risks,20,21 is more convenient for the patient and is less costly. On the other hand, PO
therapy carries a greater risk of poor adherence, gastrointestinal intolerance and variable serum levels
related to drug bioavailability.
Nonetheless, for the majority of bone and joint infections, clinicians are able to identify an appropriate PO
antibiotic regimen with high PO bioavailability and good tissue penetration. This strategy, however, has not
yet been compared with IV treatment in a large clinical trial. Therefore, we set out to address this issue.
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Initially, we conducted a single-centre pilot study that concluded in March 2013.1 The results were
reviewed by an independent Data Monitoring Committee (DMC), which advised that it was safe and
appropriate to extend the trial. Thereafter, we broadened recruitment to multiple centres and transferred
the data from the 228 participants in the pilot study to the database for a multicentre trial, the findings of
which are reported here.
The Oral versus IntraVenous Antibiotics (OVIVA) trial was funded by the Health Technology Assessment
(HTA) programme. The trial was in full compliance with the Helsinki Declaration22 and has ethics approval
(Research Ethics Committee reference number 09/H0604/109 for the single-centre pilot study and
Research Ethics Committee reference number 13/SC/0016 for the multicentre trial) from the NHS health
research authority.
Explanation of rationale
The objective of the study was to compare the efficacy and safety of IV versus PO antibiotic therapy for
patients with bone and joint infection. Six weeks of IV therapy is the current standard of care for some
or all of the patients in the hospital trusts that took part in this study. Antibiotics commonly used for
IV therapy are often not suitable for oral use (because they are not absorbed) and PO antibiotics are often
not suitable for IV use (either because an IV preparation is not available or because they require more
frequent dosing than is logistically practical with outpatient IV therapy). It would not, therefore, have been
possible simply to randomise the route of administration without this affecting the choice of antibiotic.
The choice of antibiotic was subject to patient factors, the organisms identified and the site of infection,
and the preferred antibiotic may have changed during treatment as laboratory results were returned or in
response to drug reactions. Thus, it was not feasible to develop a protocol specifying particular antibiotics
to cover each eventuality for either IV or PO antibiotic choice. In this study, therefore, we randomised
participants to an PO or IV ‘strategy’. The choice of individual antibiotics within the randomised strategy
was made by a clinician specialised in managing clinical infection and was based on bioavailability,
side effect profile, spectrum of activity and, while waiting for culture results, patient risk factors for
resistant organisms.
Health economic rationale
The objective of the health economics analysis was to explore the cost-effectiveness of IV antibiotics
compared with PO antibiotics. Cost-effectiveness is judged using incremental costs per health outcome.
Two analyses were planned in the economic evaluation: a cost–utility analysis (CUA) using quality-adjusted
life-years (QALYs) as the health outcome (cost per QALY gained) and a cost-effectiveness analysis (CEA)
using definitive failures as an outcome (cost per definitive failure averted). As PO antibiotics were found to
be non-inferior to IV antibiotics, the CEA was not carried out based on the assumption that there would
be no difference by more than the predefined non-inferiority margin in the number of definitive treatment
failures. A CEA would not be informative under these conditions. The health economic analyses focus on
the CUA, analysing differences in health-related quality of life (QALYs) and differences in costs between
treatment arms. The planned primary health economic analysis was within trial and had a time horizon
of 12 months. The intention-to-treat (ITT) population was used. The planned secondary analysis was an
extrapolation of trial results beyond the 12 months’ follow-up. However, as there was no difference in
failure rate between PO and IV antibiotics, extrapolation was not necessary, therefore, only the primary
health economic analysis is presented.
INTRODUCTION
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Chapter 2 Methods
Some of the material in this chapter has previously been published in our description of the trial.1Reproduced from Li et al.1 This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes
were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Trial design
The trial was a parallel-group, unblinded, non-inferiority multicentre (1 : 1) RCT.
Trial participants
Participants were recruited from the following 26 secondary care centres, all of which are NHS hospitals in
England and Scotland:
1. Birmingham Heartlands Hospitals
2. Bristol Royal Infirmary University Hospitals
3. Cambridge University Hospitals
4. Gartnavel General Hospital, Greater Glasgow and Clyde
5. Guy’s and St Thomas’ Hospitals, London
6. Hull and East Yorkshire NHS Trust
7. Leeds Teaching Hospitals
8. Newcastle upon Tyne Hospitals
9. NHS Lothian Hospitals, Edinburgh
10. Oxford University Hospitals
11. Royal Free Hospital, London
12. Royal National Orthopaedic Hospital, Stanmore
13. Royal Hallamshire Hospital, Sheffield
14. Royal Liverpool and Broadgreen University Hospitals
15. NHS Tayside, Dundee
16. Tunbridge Wells Hospital, Kent
17. Brighton and Sussex University Hospitals
18. Wansbeck Hospital, Northumbria
19. Medway Maritime Hospital, Kent
20. Norfolk and Norwich Hospitals
21. Queen Elizabeth Hospital, King’s Lynn
22. Blackpool Teaching Hospitals
23. Northwick Park Hospital, London
24. Northampton General Hospital
25. University Hospitals of North Midlands, Stoke on Trent
26. Whittington Hospital, London.
All sites routinely used 6 weeks of IV antibiotic therapy as their standard initial treatment for some or all
categories of bone and joint infection, and all were able to deliver IV antibiotics to patients after discharge
from hospital.
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Participants were considered for inclusion when an infection specialist reviewed a patient with a bone or
joint infection that was considered to require at least 6 weeks of antibiotic therapy. The contact was
triggered through the routine care pathway, for example following referral by a surgical team, a referral
from primary care direct to infectious disease services or by following up a laboratory result. Informed
consent was obtained from each participant by research staff, trained in good clinical practice, after
assessing their understanding of the patient information sheet (PIS). Eligibility was determined by the
following inclusion and exclusion criteria.
Inclusion criteria
The participant had to meet each of the following criteria:
1. a clinical syndrome comprising any of the following – (1) localised pain, (2) localised erythema,
(3) temperature > 38.0 °C or (4) a discharging sinus or wound
2. willing and able to give informed consent
3. aged ≥ 18 years
4. had received ≤ 7 days of IV therapy after an appropriate surgical intervention to treat bone or joint
infection (regardless of presurgical antibiotics) or, if no surgical intervention was required, the patient
had received ≤ 7 days of IV therapy after the start of planned curative treatment for the relevant
clinical episode
5. life expectancy of > 1 year
6. bone and joint infection in one of the following categories –
i. native osteomyelitis (i.e. bone infection without metalwork) including haematogenous or
contiguous osteomyelitis
ii. native joint sepsis treated by excision arthroplasty
iii. prosthetic joint infection treated by debridement and retention, by one-stage revision or by excision
of the prosthetic joint (with or without planned reimplantation)
iv. orthopaedic device or bone-graft infection treated by debridement and retention, or by debridement
and removal
v. spinal infection, including discitis, osteomyelitis or epidural abscess.
Exclusion criteria
The participant was ineligible if he or she met any one of the following criteria:
1. S. aureus bacteraemia on presentation or within the previous month
2. bacterial endocarditis, either on presentation or within the previous month (note: there were no study
mandated investigations, so participants were not required to have echocardiograms, blood cultures or
any other investigations to exclude endocarditis in the absence of a clinical indication)
3. any other concomitant infection that, in the opinion of the clinician responsible for the patient,
required a prolonged course of IV antibiotic therapy (e.g. mediastinal infection or central nervous
system infection)
4. mild osteomyelitis, defined as bone infection that, in the opinion of the physician, would not usually
require a 6-week course of IV antibiotic therapy
5. an infection for which there were no suitable antibiotic choices to permit randomisation between the
two arms of the trial (e.g. when organisms were only sensitive to IV antibiotics)
6. prior enrolment in the trial
7. septic shock or systemic features requiring IV antibiotic therapy in the opinion of the treating clinician
(the patient could be re-evaluated if these features resolved)
8. unlikely to comply with trial requirements following randomisation in the opinion of the investigator
9. clinical, histological or microbiological evidence of mycobacterial, fungal, parasitic or viral aetiology of
the infection
10. receiving an investigational medical product as part of another clinical trial.
METHODS
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The use of antibiotic-loaded cement in spacers, bone substitutes or beads at the site of infection was not an
exclusion criterion, but was recorded. Pregnancy, renal failure and liver failure were not exclusion criteria,
provided that suitable antibiotic options could be identified for both IV and PO therapy prior to randomisation.
Randomisation
An electronic randomisation service, with telephone back-up if necessary, was provided through a clinical trials
unit (CTU). After confirming the patient’s eligibility, the randomisation service assigned a sequentially allocated
study number and informed the investigator of the treatment allocation in real time and by confirmatory
e-mail. Randomisation was stratified by site to take account of variation in clinical practice between centres.
The local clinician or study nurse was responsible for documenting participants’ enrolment in their clinical
notes and for informing the participant’s general practitioner (GP).
Interventions
Eligible patients were randomised (1 : 1) to complete the first 6 weeks of antibiotic therapy with either IV
or PO antibiotic therapy. The selection of individual antibiotics within the allocated strategy (i.e. PO or IV
antibiotics) was the responsibility of the infection specialist caring for the patient, based on microbiological
assessments, the side effect profile, patient preferences and epidemiological factors suggesting the
likelihood of antibiotic resistance. In the event of a culture-negative bone or joint infection (or when there
was a delay in availability of culture results), the infection specialist selected the most appropriate empiric
therapy. When new information became available, the infection specialist was permitted to alter the choice
of antibiotic agent according to clinical need. If the participant remained within the allocated administration
strategy, they remained within protocol; if this was not possible, the participant was deemed to have met a
secondary end point (i.e. early termination of the randomised strategy).
Patients randomised to the IV strategy were expected to complete 6 weeks of IV antibiotics. When
necessary for optimal care, clinicians were permitted to use adjunctive PO agents in patients treated with
IV therapy (e.g. PO rifampicin as adjunctive therapy for biofilm-related staphylococcal infection). Patients
randomised to PO therapy were expected to commence their randomised strategy as soon as possible but
were permitted to remain on IV therapy for up to 7 days from the start of the treatment episode, which was
most commonly the date of surgical intervention, without being considered an end point. This provided
an opportunity for complete recovery from anaesthesia and for antibiotic selection based on culture
and susceptibility testing after surgery. If a participant who was randomised to PO therapy required IV
antibiotic therapy for an unrelated intercurrent illness during the initial 6 weeks of treatment, or experienced
vomiting, inability to swallow or other concern about absorption of PO medication, then IV antibiotic
therapy could be substituted for up to 5 days. If IV antibiotic prescribing exceeded the limits set in the
PO strategy, the patient was deemed to have met a secondary end point but still contributed to the ‘ITT’
analysis, and study follow-up therefore continued.
If at any point the randomised strategy (IV or PO) was no longer compatible with good clinical care,
then the study participant was withdrawn from their randomised treatment arm and an end point was
recorded. Appropriate reasons for discontinuing the allocated treatment were, for example, no suitable
medication was available within the allocated strategy because of adverse reactions, contraindications
and susceptibility testing results. Failure to maintain IV access was considered a legitimate reason for
discontinuing IV antibiotics and switching to PO antibiotics to complete the first 6 weeks. In such cases,
the event was recorded as a secondary end point, which was most commonly an early exit from allocated
treatment strategy. However, a wound discharge, superficial erythema or other clinical sign related to
infection or resolution of infection was not an appropriate indication for changing PO to IV, or vice versa,
as there was equipoise regarding efficacy.
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For any patient who was withdrawn from their randomised strategy, each case was discussed with the
study chief investigator or delegate of the chief investigator beforehand. Changing the antibiotic while
remaining within the allocated strategy did not need discussion, but such decisions were made by a
clinician with appropriate training in managing infection. Patients who were withdrawn from the allocated
strategy for any reason continued to be followed up according to the trial protocol (unless they specifically
declined this) and were included in ‘ITT’ analysis of efficacy, but not in the ‘according-to-protocol’ analysis
(unless they had completed at least 4 weeks within their randomised strategy).
Dose adjustments based on renal or hepatic function, drug interactions or other factors were permitted in
accordance with drug labelling information: the British National Formulary (BNF) and local pharmacy guidelines.
Follow-on antibiotic treatment after the initial 6 weeks was allowed in either arm of the trial, but the
choice of agent, duration and route of administration were not governed by the trial protocol.
All systemic antibiotics used (including dose, route of administration and duration) were recorded in the
case report form (CRF) from the date of randomisation to final follow-up at 1 year. Local antibiotic use in
cement or bone fillers was recorded but topical antibiotic use for superficial wounds was not.
There were no formal withdrawal criteria in this study other than at the request of a participant. All patients
were free to withdraw their consent at any time; if they elected to withdraw from the allocated treatment
strategy during the randomised treatment phase, they were deemed to have met a secondary end point but
were still followed up and included in the analysis, provided that appropriate consent had been obtained.
Assessments
Data on inclusion criteria, patient characteristics, operative details and comorbidities were collected at the
baseline/enrolment visit and entered onto the web-based database by the trial sites.
While an inpatient, study clinician or research nurse maintained contact with the clinical team to identify
potential end points, and to ensure implementation of the randomised antibiotic strategy. Following
hospital discharge, participants were seen according to clinically determined follow-up plans. Trial-specific
clinical data were obtained from either face-to-face contact with the participants or from the relevant case
records at 6 weeks (range day 21 to day 63), 4 months (range day 70 to day 180) and 1 year (range
day 250 to day 420). Research staff at the recruiting centre were responsible for entering the data from
clinical reviews. If the patient did not attend clinic within the specified date ranges, the investigator arranged
a telephone review with the participant or the participant’s GP to identify potential end points or serious
adverse events (SAEs). If, based on the telephone discussion, a further clinical review was indicated, the
investigator facilitated this and advised the patient accordingly.
A study clinician reviewed the source documents from routine care visits when completing investigator
reviews. They recorded:
l microbiology and histology results and date of discharge (first review only)
l outpatient visits since randomisation
l SAEs
l readmissions for inpatient care
l type of IV catheter (line) used and any line-related complications
l episodes of Clostridium difficile-associated diarrhoea
l antibiotic use, including dosage, route and model of care (e.g., district nurse, self-administered or daily
clinic visits)
l presence or absence of any potential end points
l reasons for not completing the planned antibiotic course (if applicable).
METHODS
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The EuroQol-5 Dimensions, three-level version (EQ-5D-3L) questionnaires to assess quality of life were
requested at baseline, day 14, day 42, day 120 and day 365. The baseline EuroQol-5 Dimensions (EQ-5D)
data were entered by the researcher and then filed in the site file. Subsequent EQ-5D questionnaires
were handed to participants with prepaid envelopes to the central CTU in Oxford for data entry and filing.
EQ-5D data were not routinely collected during the single-centre pilot study.
Oxford Hip Score (OHS) or Oxford Knee Score (OKS) questionnaires were given to patients with an
infection in the hip or knee. Returns were requested at baseline, day 120 and day 365. Baseline data were
entered at trial sites, but subsequent returns were sent directly to Oxford for data entry and filing.
A subset of participants was monitored through a Medication Event Monitoring System (MEMS). These
consist of tablet containers with a cap that records every opening with a date and time stamp, which
subsequently can be downloaded for analysis permitting monitoring of medication adherence.
Objectives
The primary objective was to determine whether or not PO antibiotics are non-inferior to IV antibiotics for
serious bone and joint infection, as judged by the proportion of patients experiencing definitive treatment
failure during 1-year of follow-up.
Secondary objectives were to compare the following end points according to treatment allocation:
1. SAEs, including death (i.e. all cause) according to treatment allocation
2. line complications (i.e. infection, thrombosis or other events requiring early removal or replacement of
the line)
3. C. difficile-associated diarrhoea
4. ‘probable’ and ‘possible’ treatment failure as composites with definitive treatment failure
5. early termination of the planned 6-week period of PO or IV antibiotics because of adverse events,
patient preference or any other reason
6. resource allocation using (1) length of inpatient hospital stay, (2) frequency of outpatient visits and
(3) antibiotic prescribing costs
7. quality of life, as evaluated by EQ-5D questionnaire
8. OHS and OKS (when infection was in the hip or knee)
9. adherence, as indicated by MEMS in a subset of participants. [In a subset of sites (i.e. Oxford University
Hospitals, Guy’s and St Thomas’ Hospitals Trust, Royal Free Hospital Trust and Royal National
Orthopaedic Hospital), PO antibiotics were dispensed to patients in pill containers with MEMS.]
Outcomes
Potential primary end points were identified through post-randomisation prospective surveillance, and
reviewed by an end-point committee blind to the treatment group. The primary end point was failure of
infection treatment, for which definite failure was indicated by one or more of the following:
1. isolating bacteria from two or more samples of bone/spine/periprosthetic tissue, when the bacteria were
phenotypically indistinguishable
2. a pathogenic organism (e.g. S. aureus but not S. epidermidis) on a single, closed aspirate or biopsy of
native bone or spine
3. diagnostic histology on bone/periprosthetic tissue
4. formation of a draining sinus tract arising from bone/prosthesis
5. recurrence of frank pus adjacent to the bone/prosthesis.
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Secondary end points were:
1. SAEs, including death (i.e. all cause) according to treatment allocation
2. line complications (i.e. infection, thrombosis or other events requiring early removal or replacement of
the line)
3. ‘probable’ or ‘possible’ treatment failure as composites with definitive treatment failure – these were
determined by a blinded end-point committee review and determined according to the
following criteria:
(a) loosening of a prosthesis, confirmed radiologically, or
(b) non-union of a fracture after 6 months, confirmed radiologically, or
(c) superficial spreading erythema, treated as cellulitis with an antibiotic for > 1 week, when results
from deep tissue samples did not meet the primary end point as described above
when appropriate, deep tissue samples were sent for microbiology and the results of culture were
negative, and either (a), (b) or (c) were met, the end point was regarded as ‘possible’. On the other
hand, when deep tissue samples were not sent for microbiology, and either (a), (b) or (c) were met,
then the end point was regarded as ‘probable’
4. early termination of the planned 6-week period of PO or IV antibiotics because of adverse events,
patient preference or any other reason
5. resource allocation determined by (1) length of inpatient hospital stay, (2) frequency of outpatient visits
and (3) antibiotic prescribing costs
6. quality of life evaluated by EQ-5D questionnaire
7. OHS and OKS (when infection was in the hip or knee)
8. adherence to PO medication.
The study clinicians determined secondary end points 1, 2, 4 and 5. The blinded end-point review
committee determined primary end points and secondary end point 3, by reviewing relevant clinical notes
redacted for personal details and any information that might have betrayed the treatment allocation.
Participant questionnaires determined secondary end points 6 and 7. Secondary end point 8 was
determined by MEMS at four sentinel sites.
Adherence and Medication Event Monitoring Systems
Patient adherence to antibiotic therapy may directly influence the outcome of treatment. In order to avoid
intrusion and to minimise undue influence on patient behaviour, participants did not receive any direct
antibiotic adherence support (such as text message reminders or telephone monitoring), but the importance
of adherence was explained at the time of recruitment and reinforced at the time of discharge. The PIS
included information written by the patient representatives explaining the importance and underlying
rationale of medication adherence.
In order to validate adherence, selected sites (i.e. Oxford University Hospitals, Guy’s and St Thomas’
Hospitals, The Royal National Orthopaedic Hospital and The Royal Free Hospital, London), dispensed PO
antibiotics in pill containers with MEMS.23,24 Sensors in the pill container lids (caps) detected opening and
closing and recorded these events with a time and date stamp. The sensor data were downloaded and
read at a later date to assess whether or not patients had opened their bottles at times consistent with
their prescription. MEMS were used only with specific consent from participants. If more than one
antibiotic was prescribed, MEMS sensors were used for the more frequently dosed antibiotic.
METHODS
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Safety
As the OVIVA trial did not involve randomisation to a specific therapy, it was not a ‘Clinical Trial of an
Investigational Medicinal Product’, as defined by the European Union directive 2001/20/EC.25 Safety
reporting therefore referred to the trial sponsor and the DMC. All SAEs identified within a year of
randomisation were recorded.
If an investigator became aware of an unexpected SAE during the trial, he or she contacted the chief
investigator who clarified clinical details and reported the SAE to the sponsor. If, in the opinion of the chief
investigator or the sponsor, an unexpected SAE might have been relevant to participant safety, a detailed
report including an assessment of causality and severity was forwarded to the DMC. In turn, the DMC
made a recommendation to the Trial Steering Committee regarding the safety of the trial in the light of
this report.
Expected SAEs that did not undergo expedited reporting were defined as:
l complications of bone/joint surgery
l complications of the bone/joint infection for which the patient was undergoing treatment (including
potential end points)
l drug reactions as detailed in the product literature [i.e. the summary of product characteristics (SmPC)
or BNF]
l drug reactions for concurrent medications given for routine clinical care as detailed in the product
literature (i.e. SmPC or BNF)
l intercurrent illness causally related to the comorbid conditions that the investigator believed were likely
diagnoses, given the patient’s history, age and other factors.
The investigators used their judgement, such that SAEs that technically met the definitions above for
expectedness, but that seemed unexpected in terms of severity, duration or other factors, may have been
reported as unexpected.
Statistical methods
Full details of the statistical methods used are detailed in a statistical analysis plan (see Appendix 1), which
was agreed and signed off prior to locking the database.
Sample size
An initial sample size estimation of 1050 was based on an expected overall failure rate of 5% and a
non-inferiority margin of 5% (or a relative increase of 100%), with a one-sided alpha = 0.05, 90% power
and 10% loss to follow-up. This was derived from short-term follow-up in the single-centre pilot study in
which 10 participants experienced a primary end point in the first 197 randomisations.
Pooled data from a planned interim analysis during the multicentre study demonstrated that the true event
rate was likely to be closer to 12.5%. To account for this, we adjusted the non-inferiority margin to 7.5%
(or a relative increase of 60%). As the final control group failure rate remained unknown, recruitment
continued as planned until October 2015 to achieve the largest possible sample size within the original
target, and to optimise the potential utility of subgroup analyses. The DMC and ethics committee
approved this as an amendment to the protocol.
Primary analysis
The proportions of participants experiencing a primary end point at 1-year follow-up (definitive treatment
failure as adjudicated by a blinded end-point review committee) were tabulated by randomised strategy
(i.e. PO vs. IV therapy). Non-inferiority was defined as the absolute, upper 90% confidence interval (CI)
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around the unadjusted difference (PO vs. IV) being < 7.5%. The primary analysis was based on the
ITT population, whereby all participants were included based on their randomised strategy (PO vs. IV
strategy). Missing end-point data were handled by multiple imputation. Supporting analysis included a
complete-case analysis, a per-protocol (PP) analysis and an analysis whereby those with missing end points
were assumed not to have experienced a definitive treatment failure. Sensitivity analyses explored the
impact of informatively missing data.
Secondary analyses
Secondary analyses focused on consistency of point estimates and 95% CI, rather than formal comparisons
with the 7.5% non-inferiority margin. Adjusted quantile regression models or rank sum tests were used
to compare continuous secondary outcomes, and proportions of participants with secondary end points
were presented (including chi-squared tests). Interaction tests were used to determine the consistency of
treatment effects by prespecified subgroups, including the type of baseline surgical procedure, infecting
pathogen and the clinician’s specified antibiotic intentions, as recorded prior to randomisation, and
whether or not this planned antibiotic regimen included rifampicin.
Deviations from the statistical analysis plan
Additional post hoc subgroup analyses performed were:
l metal retained versus no metal retained in baseline surgical procedure
l known pathogen versus pathogen unknown
l participants with and without peripheral vascular disease.
Software employed
Analyses were undertaken using Stata® (version 14SE, StataCorp LP, College Station, TX, USA).
Randomisation
A randomisation list, stratified by site and prepared by a statistician, was held securely by a CTU. The
randomisation sequence was created using Stata 12IC statistical software and was stratified by centre
with a 1 : 1 allocation using random blocks of size 8–14. Allocation concealment was achieved through
the use of sequentially allocated study numbers. After confirming a patient’s eligibility, the study clinician
contacted the CTU via a website link (with telephone back-up if required) to be provided with a study
number and the associated randomised treatment allocation (PO vs. IV for the first 6 weeks of antibiotics).
An automated e-mail confirming these data was then forwarded to the clinician randomising the patient.
All participants were randomised after confirmation of eligibility but within 7 days of the start of their
treatment episode.
Blinding
The study was open label. Blinding was not possible, as we considered that giving prolonged IV placebo
would pose an unnecessary risk to participants and, therefore, would be unethical. Because an open-label
study is at risk of bias, we appointed an end-point review committee. The end-point review committee
was composed of three independent clinicians (two infectious diseases specialists and one orthopaedic
surgeon) with expertise in the management of orthopaedic infections.
METHODS
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All relevant notes relating to a potential end point were reviewed and redacted for both personal identifiable
information and specifics of antibiotic treatment or IV line insertion, which could have indicated the route of
administration of antibiotics. The end-point review committee was therefore blind to treatment allocation.
The redacted notes were forwarded to the end-point review committee, which examined them against
objective criteria, to determine whether or not an end point had been met, either by consensus or by a vote
called by the chairperson if consensus could not be reached.
The end-point review committee was only required to review definite or potential treatment failures.
All other end points were determined directly by the local study clinicians.
Summary of changes to the project protocol
l Adjustment of non-inferiority margin as described under Sample size.
l Extension of recruitment period at no additional cost.
Health economic analysis methods
The economic evaluation is based on health-care resource use and quality-of-life data collected during the
trial. All costs and health outcomes were measured and collected within 1 year, so that no discount rate
was applied.
Resource use
Costs were measured from a NHS and Personal Social Services perspective. Resource use included
antibiotic medication, IV administration and complications, and inpatient stays. These were completed for
the time periods of 42, 120 and 365 days following randomisation. Costs for medication were obtained
from the BNF.26 Inpatient stays were valued using NHS reference costs27 and IV administration resources
and costs were taken from the literature28,29 and adjusted for inflation using the Hospital and Community
Health Index.30 Costs were reported for 2015 in Great British pounds. Antibiotic resource use includes all
antibiotics prescribed to each participant in the 12-month follow-up period. Inpatient stays are per bed-day,
and IV administration includes the cost of IV line insertion and removal for each IV episode per participant,
cost of line complications when a new line is needed and the cost of the outpatient parenteral antimicrobial
therapy (OPAT) team, if applicable.
Total costs per participant were calculated by assigning unit costs to within-trial resource use for each
participant.29 Unit costs and their sources are presented in Table 1.
Health outcomes
Outcomes are measured using QALYs. QALYs are a combination of both quality and length of life.
Quality-of-life data were collected using the EQ-5D-3L,31 administered at baseline, at 14 days, 42 days,
120 days and 365 days and if an end point or SAE occurred. The EQ-5D data collected when a SAE occurred
were subsequently not used, as the available data were insufficient to provide additional information for the
analysis. The EQ-5D-3L is a generic quality-of-life measure comprising five questions and a visual analogue
scale (VAS). The questions cover five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/
depression. There are three levels of severity for each domain (‘no pain’, ‘moderate pain’ and ‘extreme pain’).
The EQ-5D instrument provides 243 predefined health states. Responses are pooled into a three-digit number
labelling the respondent’s health state (from ‘111’, meaning no health-related problems, to ‘333’, meaning
extreme health-related problems in all five domains).32
The EQ-5D-3L responses were converted to utility measures using the tariff developed for the UK general
population.33 This utility is combined with the length of time the person is in each health state using
standard area-under-the-curve methods to calculate QALYs. Patient-specific QALYs were estimated using
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utility values from each follow-up point and weighting each time interval by the patient’s utility during that
period. A utility score of 1 is equivalent to full health and 0 is equivalent to death. It is possible to have a
negative utility score, for which the patient’s health state is worse than death. Discrete changes in utility
values between follow-up time points were assumed to be linear.
Analysis
The total cost per participant in each intervention was summed and divided by the number of participants
in each arm to calculate the mean cost per participant in each arm, along with the difference in means
and 95% CI.
The mean QALY per participant for each intervention was calculated by summing all participants’ QALYs
and dividing by the number of participants in that intervention arm. The difference in the means was
calculated along with 95% CIs.
The analysis was carried out in Stata version 14.0. Complete cases were analysed initially and multiple
imputation was used to explore the effect of missing data on the analysis.
Missing data
The nature of the missing data was analysed and an appropriate method to replace missing data utilised.34,35
Missing data for resource use and EQ-5D-3L were handled using multiple imputation, which requires less
strong assumptions than complete-case analysis. Multiple imputation requires a more relaxed assumption
that data are missing at random. The probability of having missing data is independent of unobserved
values and the missing data may depend on observed data.36 Missing resource and quality-of-life data were
imputed using multiple imputation by chained equation.37
The regression analyses used to impute missing data included information on ‘baseline surgical procedures’.
TABLE 1 Unit costs and sources
Resource Unit cost Source
Antibiotic Various BNF26
Inpatient stay £295.80 per overnight stay NHS Reference Costs 2014 to 201527
IV administration
Insertion: PICCa £190 Expert opinion
Removal £34.12 Expert opinion
OPAT type
District nurse £58 per hour NHS Reference Costs 2014 to 201527
Infusion centre attendance £109 per hour NHS Reference Costs 2014 to 201527
PICC, peripherally inserted central catheter.
a Only six patients were reported to have a Hickman line inserted and the majority of patients had a PICC. To be
consistent within the IV arm of the trial, we assumed a constant cost for a PICC for all patients. A Hickman line is likely
to increase costs only marginally in the IV arm as these lines involve a surgeon’s time to be inserted.
Reproduced with permission from McMeekin et al.29 © 2019 McMeekin et al. This is an open access article distributed
under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
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The following assumptions were made:
l the cost of a line insertion and removal was applied to the initial 6-week period of the intervention.29
In addition, it was assumed that an IV episode with a gap of ≤ 2 days between IV drugs did not require
a new line to be inserted and a cost was not applied for insertion/removal; if the gap between episodes
was > 2 days, it was assumed that a new line had to be inserted and the old line was removed, and a
cost was assigned accordingly
l the OPAT type recorded at the 42-day follow-up visit was used for each participant for all IV episodes
in the 12-month follow-up period29
l any durations of antibiotics, IV episodes and inpatient stays per participant were truncated at
365 days, as the follow-up period is 365 days
l OPAT costs were applied at 1 hour per day, if applicable
l participants with an OPAT type of ‘infusion centre’ had a weighted cost of two out of five to
self-administrating and three out of five to district nurse applied to the length of IV episode following
discharge from hospital; this was the proportion of district nurse to self-administering OPAT witnessed
in the trial
l for participants with missing data for OPAT type, a weighted average cost of two out of five to
self-administrating and three out of five to district nurse was applied to the length of IV episode
l for participants with missing data for IV line type, the cost of a peripherally inserted central catheter
line was used as this was used by the majority of participants during the trial.
Sensitivity analysis
Instead of using the above weighted average for participants with missing OPAT type, two scenarios were
explored: applying solely the cost of a district nurse, and applying solely the cost of self-administration.
To explore the uncertainty around the cost and QALY differences and the resulting incremental
cost-effectiveness ratio (ICER), a non-parametric bootstrapping technique was employed with 1000 iterations.
Results are presented using a cost-effectiveness plane, showing all 1000 cost-effectiveness pairs.
Long-term outcomes
Owing to the non-inferiority margin being met in the trial, the extrapolation of failure rates was not carried
out as there would have been no difference in rates extrapolated forward.
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Chapter 3 Results
Recruitment
The timeline of recruitment into the study was as follows:
l date of start of recruitment – 26 March 2013, start of main study; 3 June 2010, start of internal pilot
l date of end of recruitment – 31 October 2015
l date of end follow-up – 31 October 2016
l date of final analysis – 1 November 2016–20 January 2017
l target number of subjects – 1054 (527 per arm) including the pilot.
Originally, recruitment to the OVIVA study was to conclude at the end of October 2014. Owing to the
initial recruitment being lower than expected, the trial was granted an extension without additional
funding. The above presented timelines take into account this extension.
Study participants
Information on screening, eligibility, randomisations and follow-up is shown in the Consolidated Standards
of Reporting Trials (CONSORT) flow diagram in Figure 1.
Screening logs were only available in the multicentre study and not all sites completed screening logs
adequately. Therefore, the CONSORT flow diagram may overestimate conversion rates from screened to
eligible and eligible to randomised participants.
Participants were excluded from the PP population if they received < 4 weeks of their allocated strategy for
reasons other than possible or probable recurrence of infection and/or had missing data for the primary
end point.
Data quality
Data collection and compliance
Data on inclusion criteria, patient characteristics, operative details and comorbidities were collected at the
baseline/enrolment visit and entered onto the web-based database by the trial sites.
Three clinical reviews were performed for each participant during the follow-up:
l day 42 (accepted range day 21–63)
l day 120 (accepted range day 70–180)
l day 365 (accepted range day 250–420).
Clinical assessment compliance
Table 2 shows the data completeness for clinical assessments at three follow-up points. The number of
missing baseline and follow-up CRFs may not coincide with the number of participants withdrawn or lost
to follow-up at the relevant assessment time point. This is because CRFs could be completed to indicate
participant withdrawal and loss to follow-up, as well as to record relevant clinical data up to the time of
withdrawal/loss to follow-up.
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Not eligible
(n = 628)
• S. aureus bacteraemia, n = 54
• Bacterial endocarditis, n = 29
• Concomitant infection mandating IV
   therapy, n = 43
• Mild disease requiring < 6/52 antibiotics,
   n = 182
• No suitable PO regimen available, n = 80
• Previous enrolment in the trial, n = 10
• Shock or other features mandating long IV
   therapy, n = 28
• Unlikely to comply with trial requirements,
   n = 74
• Mycobacterial, fungal, parasitic or viral
   aetiology, n = 6
• Receiving an investigational product in
   another trial, n = 0
• Reasons not reported, n = 122
Assessed for eligibility
(n = 2077)
Not randomised
(n = 395)
• Prefer IV, n = 72
• Prefer PO, n = 44
• OPAT out of area, n = 19
• Doctors not in 
   agreement, n = 6
• Left to go abroad,
   n = 10
• Transferred to another
   hospital, n = 8
• Other, n = 49
• Declined without
   providing further
   reason, n = 187
Enrolment
Eligible
(n = 1449)
Randomised
(n = 1054)
Allocated to IV
(n = 527)
Received at least 4 weeks of their allocated
strategy, n = 458
Lost to follow-up
(n = 22)
Analysed (ITT) in
primary analysis
(n = 527)
Reasons
• Patient withdrew from trial, n = 7
• Patient was lost to follow-up, n = 5
• Patient died,a n = 10
Excluded from the primary analysis, n = 0
Follow-up
Allocation
Analysis
Analysed in PP analysis
(n = 443)
Excluded from PP 
(n = 84) 
• End-point data missing, n = 15
• < 4 weeks of allocated strategy for 
   reasons other than possible or 
   probably recurrence, n = 63
• Both, n = 6
• End-point data missing, n = 13
• < 4 weeks of allocated strategy for 
   reasons other than possible or 
   probably recurrence, n = 43
• Both, n = 5
Allocated to PO
(n = 527)
Received at least 4 weeks of their allocated
strategy, n = 478
Lost to follow-up
(n = 20)
Analysed (ITT) in 
primary analysis
(n = 527)
Reasons
• Patient withdrew from trial, n = 7
• Patient was lost to follow-up, n = 7
• Patient died,a n = 6
Excluded from the primary analysis, n = 0
Analysed in PP analysis
(n = 466)
Excluded from PP 
(n = 61) 
FIGURE 1 The OVIVA trial CONSORT flow diagram. a, An additional seven deaths were reported within the
acceptable range for the day 365 follow-up. The final follow-up for these participants is not considered missing.
These deaths are reported in Serious adverse events.
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Questionnaire compliance
Some potential participants were willing to take part in the trial, but were unwilling to complete
quality-of-life data. This contributed to the low compliance rate for the questionnaires (Table 3).
Although not routinely collected from 228 participants in pilot phase of the OVIVA study, 122
questionnaires were received for these participants (1 at day 14, 74 at day 42, 32 at day 120 and 15 at
day 365). These data were included in the analysis of the EQ-5D-3L.
Table 4 displays the number of participants for whom the OHS and OKS could be calculated at the
relevant time points. The OHS and OKS could be calculated when up to two items are missing. A low
number of additional questionnaires were received for which the calculation of the OHS was not possible
owing to missing items (4 at baseline, 2 at day 120 and 2 at day 365). A low number of additional
questionnaires were received for which the calculation of the OKS was not possible owing to missing items
(3 at day 120 and 2 at day 365). These questionnaires were not classed as complete and are not included
any of the subsequent summaries and analyses.
Baseline characteristics
Trial site was the only stratification factor for randomisation in this trial. Tables 5 and 6 provide an
overview of the baseline data. As these data were collected on different CRFs, not all data were available
for all randomised participants.
TABLE 3 The EQ-5D compliance for OVIVA2a participants
Assessment
Antibiotics
IV PO Total
Complete Expected % Complete Expected % Complete Expected %
Baseline 386 414 93.24 388 412 94.17 774 826 93.70
Day 14 307 414 74.15 308 412 74.76 615 826 74.46
Day 42 326 414 78.74 336 412 81.55 662 826 80.15
Day 120 295 414 71.26 286 412 69.42 581 826 70.34
Day 365 285 414 68.84 276 412 66.99 561 826 67.92
a This table summarises EQ-5D-3L data availability for pariticipants recruited after the pilot study.
TABLE 2 Data compliance for clinical assessments
Assessment
Antibiotics
IV PO Total
Complete Expected % Complete Expected % Complete Expected %
Baseline 527 527 100.00 527 527 100.00 1054 1054 100.00
Day 42 523 527 99.24 523 527 99.24 1046 1054 99.24
Day 120 517 527 98.10 521 527 98.86 1038 1054 98.48
Day 365 514 527 97.53 517 527 98.10 1031 1054 97.82
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Table 7 shows information on histology and microbiology results and the diagnostic certainty of infection
as determined by baseline criteria. Although these samples were taken at trial entry, data were collected
at the day 42 CRF. Therefore, data for eight participants were missing, as this form was received for only
1046 participants. One further participant, who was withdrawn soon after randomisation, also has missing
data for their histology and microbiology. This accounts for nine missing data points in this table. For those
participants who did not fulfil the predefined definition for definite infection, an independent blinded
committee reviewed the case records to assign categorisation.
Note that there were participants who did not fulfil the definition of infection at baseline in accordance
with the protocol but who were treated for infection on clinical grounds. These participants are
summarised under ‘infection status unclear’. A decision was made by the trial team to include these
participants into the ‘possible infection’ category in all subsequent summaries.
Numbers analysed
The following patient populations were utilised in the analysis:
Intention to treat
All randomised participants were analysed according to their allocated intervention.
Modified intention-to-treat analysis
All randomised participants with both baseline and at least one post-baseline assessment for patient
reported outcomes. For all other outcomes, randomised participants with at least one post-baseline
assessment. Participants were excluded from this analysis if relevant baseline covariates (when relevant)
were not available. In other words, the modified intention-to-treat analysis (MITT) population was the
complete-cases subset of the ITT population.
Per protocol
The PP population was defined as all participants who received at least 4 weeks of their randomised strategy
and, if in the PO group, did not exceed the limits set for the use of IV antibiotics (i.e. 5 continuous days
at any one time). Participants who were recorded to have exited early from their randomised strategy owing
to possible or probable recurrence of infection were also included in the PP population. Participants were
included in the PP analyses if sufficient outcome and baseline data (when relevant) were available.
TABLE 4 Oxford Hip and Oxford Knee Scores
Assessment
Antibiotics
IV PO Total
Complete Expected % Complete Expected % Complete Expected %
OHS
Baseline 74 87 85.06 71 81 87.65 145 168 86.31
Day 120 64 87 73.56 59 81 72.84 123 168 73.21
Day 365 60 87 68.97 57 81 70.37 117 168 69.64
OKS
Baseline 99 111 89.19 88 98 89.80 187 209 89.47
Day 120 75 111 67.57 69 98 70.41 144 209 68.90
Day 365 75 111 67.57 67 98 68.37 142 209 67.94
RESULTS
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TABLE 5 Baseline characteristics
Trial site and characteristicsa
Antibiotic, n (%)
Total
(N= 1054), n (%)IV (N= 527) PO (N= 527)
Oxford University Hospitals 256 (48.58) 256 (48.58) 512 (48.58)
Bristol Royal Infirmary 3 (0.57) 3 (0.57) 6 (0.57)
Western General Hospital Edinburgh 5 (0.95) 3 (0.57) 8 (0.76)
Guy’s and St Thomas London 19 (3.61) 17 (3.23) 36 (3.42)
Royal Free London 23 (4.36) 22 (4.17) 45 (4.27)
Queen Elizabeth Hospital King’s Lynn 0 (0.00) 1 (0.19) 1 (0.09)
Royal Liverpool University Hospital 36 (6.83) 34 (6.45) 70 (6.64)
Addenbrookes Hospital Cambridge 25 (4.74) 24 (4.55) 49 (4.65)
Royal Hallamshire Hospital Sheffield 2 (0.38) 0 (0.00) 2 (0.19)
Royal Victoria Infirmary Newcastle 1 (0.19) 1 (0.19) 2 (0.19)
Ninewells Hospital Dundee 7 (1.33) 7 (1.33) 14 (1.33)
Gartnaval Hospital Glasgow 23 (4.36) 21 (3.98) 44 (4.17)
Birmingham Heartlands 23 (4.36) 25 (4.74) 48 (4.55)
Royal National Orthopaedic Hospital Stanmore 63 (11.95) 63 (11.95) 126 (11.95)
Hull Royal Infirmary 5 (0.95) 6 (1.14) 11 (1.04)
Medway Hospital 0 (0.00) 2 (0.38) 2 (0.19)
University Hospital of North Staffordshire 0 (0.00) 1 (0.19) 1 (0.09)
Leeds General Infirmary 14 (2.66) 14 (2.66) 28 (2.66)
Northampton General Hospital 4 (0.76) 1 (0.19) 5 (0.47)
Maidstone and Tunbridge Wells 1 (0.19) 3 (0.57) 4 (0.38)
Royal Sussex County Hospital Brighton 2 (0.38) 5 (0.95) 7 (0.66)
Northumbria NHS Trust 5 (0.95) 8 (1.52) 13 (1.23)
Norfolk and Norwich University Hospital 4 (0.76) 2 (0.38) 6 (0.57)
Blackpool Teaching Hospitals 2 (0.38) 4 (0.76) 6 (0.57)
Northwick Park London 3 (0.57) 3 (0.57) 6 (0.57)
Whittington Hospital London 1 (0.19) 1 (0.19) 2 (0.19)
Gendera
Male 320 (60.72) 358 (67.93) 678 (64.33)
Female 207 (39.28) 169 (32.07) 376 (35.67)
Age (years)b 61 (49–70) (18–92) 60 (49–70) (18–91) 60 (49–70) (18–92)
a Frequency and percentages are displayed.
b Median, interquartile range and range are displayed.
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TABLE 6 Baseline summaries: data collected at enrolment visit
Clinical variable
Antibiotic
Total
(N= 1054a),
n (%)
IV (N= 527a),
n (%)
PO (N= 527a),
n (%)
Information on inclusion criteriab
Localised pain 397 (75) 403 (76) 800 (76)
Localised erythema 226 (43) 207 (39) 433 (41)
Temperature > 38.0 °C 62 (12) 62 (12) 124 (12)
Discharging sinus/wound 296 (56) 285 (54) 581 (55)
Information on the baseline surgical procedure
Chronic osteomyelitis debrided, no current implant or device 153 (29) 169 (32) 322 (31)
Chronic osteomyelitis as above, but not debrided 25 (4.7) 29 (5.5) 54 (5.1)
Implant or device present and retained 124 (24) 123 (23) 247 (23)
Removal of orthopaedic device for infection 89 (17) 78 (15) 167 (16)
Prosthetic joint implant removed 68 (13) 67 (13) 135 (13)
Prosthetic joint implant, one-stage revision 47 (8.9) 43 (8.2) 90 (8.5)
Discitis/spinal osteomyelitis/epidural abscess debrided 8 (1.5) 5 (1.0) 13 (1.2)
Discitis/spinal osteomyelitis/epidural abscess but not debrided 13 (2.5) 13 (2.5) 26 (2.5)
Information on anatomical site affected by the infection
Left 225 (43) 240 (46) 465 (44)
Right 252 (48) 241 (46) 493 (47)
Bilateralc 50 (9.5) 46 (8.7) 96 (9.1)
Further information on anatomical sited
Spinal infection 37 (7.0) 35 (6.6) 72 (6.8)
Upper limb infection 43 (8.2) 59 (11) 102 (9.7)
Lower limb infection 436 (83) 419 (80) 855 (81)
Other area of infection 12 (2.3) 14 (2.7) 26 (2.5)
Details on lower limb infectionse n = 436 n = 418 n = 854
Hip 110 (25) 104 (25) 214 (25)
Knee 133 (31) 115 (27) 248 (29)
Foot 89 (20) 86 (21) 175 (20)
Other area of lower limb infection 105 (24) 113 (27) 218 (26)
Operative findings
Draining sinus arising from bone/prosthesis 177 (34) 142 (27) 319 (30)
Frank pus adjacent to bone/prosthesis 179 (34) 186 (35) 365 (35)
Information on local antibiotics used during the operation
No 360 (68) 348 (66) 708 (67)
Cement 129 (24) 109 (21) 238 (23)
Beads 36 (6.8) 69 (13) 105 (10)
Missingf 2 (0.38) 1 (0.19) 3 (0.28)
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TABLE 6 Baseline summaries: data collected at enrolment visit (continued )
Clinical variable
Antibiotic
Total
(N= 1054a),
n (%)
IV (N= 527a),
n (%)
PO (N= 527a),
n (%)
Antibiotics added to the cement during the operation n = 165 n = 178 n = 343
Gentamicin 86 (52) 99 (56) 185 (54)
Vancomycin 29 (18) 31 (17) 60 (17)
Tobramycin 5 (3.0) 12 (6.7) 17 (5.0)
Other
g
34 (21) 30 (17) 64 (19)
Missingh 11 (6.7) 6 (3.4) 17 (5.0)
Comorbiditiesb,i
Diabetes 107 (20) 98 (19) 205 (19)
Renal failure 11 (2.1) 11 (2.1) 22 (2.1)
Ischaemic heart disease 43 (8.2) 45 (8.5) 88 (8.4)
Peripheral vascular disease 31 (5.9) 32 (6.1) 63 (6.0)
Previous stroke or TIA 19 (3.6) 22 (4.2) 41 (3.9)
Dementia 1 (0.19) 1 (0.19) 2 (0.19)
Immunosuppressing medication 28 (5.3) 17 (3.2) 45 (4.3)
HIV infection (if tested for) 1 (0.19) 3 (0.57) 4 (0.38)
Rheumatoid arthritis or systemic autoimmune disease 47 (8.9) 38 (7.2) 85 (8.1)
Current smoker 61 (12) 79 (15) 140 (13)
Malignancy (curent or diagnosed within the last 2 years) 17 (3.2) 17 (3.2) 34 (3.2)
HIV, human immunodeficiency virus; TIA, transient ischaemic attack.
a Number included in each summary, unless indicated otherwise.
b The inclusion categories are not mutually exclusive.
c This figure includes spinal and pelvic osteomyelitis.
d For one participant in the IV arm, infections were reported in both the upper and lower limbs. Therefore, the total
number of infections in the IV arm add up to 528 instead of 527.
e One participant reported an infection in both the knee and hip.
f Information on antibiotic cement/beads used was unavailable for three participants.
g Of these, 52 participants received a combination of gentamicin and vancomycin, six received an aminoglycoside in
combination with another agent and the antibiotic was not stated in six cases.
h Information on antibiotics used intraoperatively was unavailable for 17 participants.
i Of note, when a specific comorbidity was not indicated for a participant, this participant was assumed to not suffer from
this comorbidity.
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TABLE 7 Baseline summaries: histology and microbiology data and infection status
Symptom or sign
Antibiotic
Total
(n= 1054)aIV (n= 527)a PO (n= 527)a
Deep tissue histology resultb
Infected 266 (50.47) 277 (52.56) 543 (51.52)
Equivocal 13 (2.47) 17 (3.23) 30 (2.85)
Uninfected 31 (5.88) 32 (6.07) 63 (5.98)
Not done 212 (40.23) 197 (37.38) 409 (38.80)
Missingc 5 (0.95) 4 (0.76) 9 (0.85)
Deep tissue microbiology resultb
≥ 2 samples positive with the same organism 357 (67.74) 338 (64.14) 695 (65.94)
≥ 2 samples taken but only 1 sample positive with a given
pathogenic organism
20 (3.80) 32 (6.07) 52 (4.93)
Only 1 sample taken which is positive for a pathogenic organism
via closed biopsy
25 (4.74) 30 (5.69) 55 (5.22)
Culture negative 77 (14.61) 78 (14.80) 155 (14.71)
≥ 2 samples taken but only 1 sample positive with a given
non-pathogenic organism
21 (3.98) 25 (4.74) 46 (4.36)
Not doned 22 (4.17) 20 (3.80) 42 (3.98)
Missingc 5 (0.95) 4 (0.76) 9 (0.85)
Results from the deep tissue microbiology (when available) (n = 500) (n = 503) (n = 1003)
S. aureus presentb 196 (39.20) 182 (36.18) 378 (37.69)
Coagulase-negative Staphylococcus presentb 137 (27.40) 135 (26.84) 272 (27.12)
Streptococcus species presentb 72 (14.40) 73 (14.51) 145 (14.46)
Pseudomonas species presentb 28 (5.60) 23 (4.57) 51 (5.08)
Other Gram-negative organism(s) presentb 84 (16.80) 84 (16.70) 168 (16.75)
Infection status at presentb
Definite infection 478 (90.70) 476 (90.32) 954 (90.51)
Probable infection 13 (2.47) 10 (1.90) 23 (2.18)
Possible infection 30 (5.69) 27 (5.12) 57 (5.41)
Infection status unclear 6 (1.14) 13 (2.47) 19 (1.80)
Missinge 0 (0.00) 1 (0.19) 1 (0.09)
a Number included in each summary, unless indicated otherwise.
b Frequency and percentages are displayed.
c Day 42 CRFs were not received for eight randomised participants. The relevant fields were not completed for one further
participant who withdrew consent soon after randomisation.
d These figures include participants who did not have surgical intervention.
e No baseline infection data were available for one participant (OV2019), who was consented in error and withdrawn
immediately after randomisation.
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Compliance
Treatment compliance
Compliance with the randomised strategy, including early exit, are secondary end points and are
summarised in the results section.
Withdrawals and protocol violations
Withdrawals and losses to follow-up
Out of the 1054 randomised participants, 42 (3.98%) were reported as withdrawn or lost to follow-up.
Follow-up for these participants ceased for the following reasons:
l participant withdrew from study, n = 14
l participant lost/did not attend scheduled clinic visits and was no longer contactable, n = 12
l patient had died, n = 16.
An additional seven deaths were reported within the acceptable range for the day 365 follow-up.
The final follow-up for these participants is not considered missing. These deaths are reported in Serious
adverse events.
Additional information on withdrawals and losses to follow-up by treatment arm can be found in the
CONSORT statement. End-point data are available for three of these participants.
Protocol violations/deviations
The trial team are not aware of any protocol violations to date. The following 19 protocol deviations occurred:
l One participant who lacked capacity to provide personal informed consent was recruited in error. The
participant was immediately withdrawn from further study related activity and all subsequent data were
recorded as missing.
l One participant was recruited despite having had staphylococcal bacteraemia within the 30 days prior
to randomisation. The participant had completed the course of therapy for bacteraemia by the time he
was recruited to the trial. He was retained in the trial despite this deviation from the protocol.
l One participant was randomised on two separate occasions, once in the pilot study and once in the
multicentre study. This patient was withdrawn from further study-related activity following realisation
of the error and all subsequent data were recorded as missing.
l Eight participants (four in each arm) were discontinued early from their randomised strategy without
an appropriate explanation. In all cases, a change to the prescription arose either as a result of an
administrative error or on the advice of a clinician who was not involved with the OVIVA trial.
l Seven patients randomised to PO therapy switched to their randomised strategy beyond the 7 days
allowed from start of treatment episode. The median delay in IV to PO switch from the start of the
treatment episode in these patients was 12 days (range 10–19 days).
l One participant randomised to IV therapy started their IV treatment 8 days after the start of the
treatment episode.
Blinding
Blinding was not applicable to the study; participants, clinical staff and the trial team were not blinded to
the randomised intervention.
The independent end-point review committee was blinded: end points were assessed based on patient
notes provided by trial sites, which were subsequently redacted by the trial staff at Oxford. Only one
incident of unblinding was reported (OV1053). This unblinding was accidental and occurred as a result of
inadequate redaction of notes. No other issues were reported by the blinded reviews.
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Primary analyses
Analysis using multiple imputation utilising all randomised participants
The frequency and proportions of participants experiencing primary end points (i.e. definitive treatment failures
as identified by the independent end-point review committee), as well as those for whom the end-point data
were missing because of participants withdrawing from the trial or being lost to follow-up prior to the 1-year
post randomisation assessment, are shown in Table 8. This summary includes all randomised participants.
The results from the primary analysis and the supporting analyses are displayed graphically in Figure 2.
The non-inferiority margin of 7.5% is indicated by the dashed line.
TABLE 8 Definite treatment failures
Analysis
Number (rate) of definitive treatment
failures, n (%)
Risk difference (90% CI)IV antibiotic PO antibiotic
ITT population (all randomised participants,
N= 1054)a
74 (14.04)
[Missing:b 21 (3.98)]
67 (12.71)
[Missing:b 18 (3.42)]
–1.38% (–4.94% to 2.19%)c
MITT subset (all participants with available
outcome data, N = 1015)c
74 (14.62) 67 (13.16) –1.46% (–5.03% to 2.11%)
All randomised participants, assuming no
definite treatment failures for those with
missing outcome data (N = 1054)d
74 (14.04) 67 (12.71) –1.33% (–4.78% to 2.12%)
PP population (N= 909)e 69 (15.58) 61 (13.09) –2.49% (–6.31% to 1.34%)
a Number of participants included: IV, n = 527; PO, n= 527.
b The number of participants with missing outcomes is 39, as opposed to 42, which is the number of participants without
a final trial assessment. This is because three participants without a final trial assessment did have definitive treatment
failure early in the trial, and end-point data are, therefore, available for them.
c This risk difference was calculated using multiple imputation to account for missing data.
d Number of participants included: IV, n = 506; PO, n= 509.
e Number of participants included: IV, n = 443; PO, n= 466.
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FIGURE 2 Forest plot of risk differences (95% CI) by analyses performed (PO vs. IV).
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Adjusted logistic regression model
The model uses the occurrence of definite treatment failure as adjudicated by the blinded end-point review
committee as the outcome and adjusts for randomised strategy, age, comorbidity (when sufficient
observations are available), infecting pathogen and baseline surgical procedure.
The baseline surgical procedures have been categorised as follows:
1. chronic osteomyelitis debrided, no current implant or device
2. discitis/spinal osteomyelitis/epidural abscess debrided
3. chronic osteomyelitis as above but not debrided, or discitis/spinal osteomyelitis/epidural abscess but
not debrided
4. implant or device present and retained [i.e. debridement, antibiotics and implant retention (DAIR)]
5. removal of orthopaedic device for infection
6. prosthetic joint implant removed
7. prosthetic joint implant, one-stage revision
8. the OVIVA trial infection criteria not met.
When participants fall into more than one category, they were assigned to the lowest numeric category in
the above list. Categories with very low counts were combined with the next (lower) category.
All randomised participants are included in this model by using multiple imputation for missing outcome data.
Insufficient incidence of comorbidities were observed for dementia and HIV (human immunodeficiency virus)
infection. Infecting pathogen and baseline surgical procedure were categorised as defined in the section on
primary end points.
There was no evidence of effect of the randomised strategy on the odds of experiencing a definitive
treatment failure during the trial follow-up. The quantile regression models are adjusted for covariates. The
covariate adjustment aims to separate the effect of the randomised intervention from other factors that
may also have an influence on the odds of participants experiencing a definitive treatment failure during
the trial follow-up. Low numbers may have been included in some levels of the categorical explanatory
variables; the coefficients therefore have low power and should be interpreted cautiously.
Diagnostic checks demonstrated that the model has limited predictive ability (pseudo-R2 = 4%). However,
the main purpose of the model was to obtain an average treatment effect, rather than to obtain accurate
predictions for individual participants, and adequate goodness of fit was demonstrated when comparing
the average predicted and observed probabilities of treatment failures in either arm. Lowess plots
demonstrated linear relationships between the independent variables and the predictors. Investigation of
the residuals showed some departure from normality; the majority of the residuals, except those at either
end of the range of linear predictions, seemed independent from predicted values.
Time-to-event modelling
To assess any potential bias in the post-randomisation surveillance, which would present as a delay in
time to meeting an end point in one randomised group or loss to follow-up or death without an event,
a time-to-event analysis was performed.
This analysis focused on the timing of definitive treatment failures and was not adjusted for baseline
characteristics. Six participants were withdrawn immediately after randomisation. They are therefore not
included in the following summaries.
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The data entered under the ‘date of review’ for the day 365 assessment were used as the date at which
the follow-up was censored for participants who did not experience a definitive treatment failure and who
were not lost to follow-up. In some instances, these reviews were performed retrospectively, and the data
entered reflect the timing of the review instead of the date at which data for the relevant participants
were reviewed (i.e. a date within the follow-up window for the day 365 visit). Therefore, the time from
randomisation to the final assessment was capped at 420 days.
There was no evidence to suggest that the hazard ratio between the treatment arms was statistically
significantly different from 1. This suggests that there was no post-randomisation surveillance bias
between the trial arms.
The Kaplan Meier curves in Figure 3 show the definitive treatment failure-free time-to-event rates. Again,
there does not seem to be any evidence to suggest that the time to definitive treatment failure differed
between trial arms.
The test for the proportional hazards assumption, as well as log-log plots, indicate that the proportional hazards
assumption is met (for the majority of the plot, i.e. the time where the majority of treatment failures occur).
Adjustment of p-values for multiple testing
There was no multiple testing, as only a single primary outcome was considered. All additional analyses
were undertaken with an intention to further inform the results from the primary analysis. Therefore,
significance levels used were 0.05, and 95% CIs were reported.
The DMC reviewed interim summaries and a formal interim analysis; however, it was expected that the
DMC would only recommend early stopping if there was a very significantly worse outcome in the
PO antibiotic group compared with the IV group (i.e. guided by the Haybittle–Peto stopping boundary).
Therefore, the significance level used to determine early termination of the trial is very low (i.e. 0.001)
and no formal adjustment of the p-value for the final analysis was considered necessary.
Missing data
Missing data were taken into account in the primary analysis, based on the ITT population, using multiple
imputation. This was described in detail in the statistical analysis plan (see Appendix 1).
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FIGURE 3 Kaplan–Meier curves for time to treatment failure by randomised strategy.
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The multiple imputation and the MITT (complete-cases ITT) analyses make the assumption that data are
missing at random. The sensitivity analysis looks at the impact of informatively missing data, assuming that
data are missing not at random.
In addition to the assumptions made in the above supporting analyses (i.e. assuming no definitive failures
for all participants with missing end-point data), this sensitivity analysis considers two extreme missing not
at random assumptions (best-case/worst-case scenarios).
The first missing not at random sensitivity analysis makes the assumption that all participants with missing
end-point data in the PO arm had a definitive treatment failure, while those with missing end-point data in
the IV arm did not have a definitive treatment failure.
The second missing not at random sensitivity analysis makes the assumption that all participants with missing
end-point data in the PO arm had no definitive treatment failure, while those with missing end-point data in
the IV arm had a definitive treatment failure.
The sensitivity analyses did not alter the results from the primary trial analysis and, therefore, did not change
the overall conclusions of the trial (i.e. that the non-inferiority criteria were met). Therefore, the trial results
are robust to missing data.
Prespecified subgroup analysis
All subgroup analyses are based on the MITT population. Subgroup analyses for definite/probable/possible
infection at baseline are repeated for the PP population.
Odds ratios were obtained from logistic regression models using definitive treatment failure as the dependent
variable, and treatment allocation, the relevant subgroup as well as the interaction term as the only covariates.
The number of treatment failures by treatment arm observed in some of the subgroups were low.
Therefore, some of the interaction effects may not be very robust (as indicated by wide CIs) or cannot be
included in the plots.
Figure 4 summarises all subgroup analyses, showing the point estimates of the odds ratios, the 95% CIs
and the numbers included in the analyses.
Based on the analysis, there was no evidence to suggest a statistically significant difference in the odds of
treatment failure between the treatment arms. Odds ratios of > 1 favour IV therapy (i.e. indicate that the
odds of experiencing a treatment failure in the PO arm were higher than the odds in the IV arm), whereas
odds ratios of < 1 favour PO therapy.
Prespecified subgroup analysis considering infection subgroups
at randomisation
Subgroup analysis of definite versus probable/possible infection at baseline
Modified intention-to-treat analysis analysis (complete-cases intention to treat)
A total of 1015 participants were included in this subgroup analysis.
The odds ratio of definitive treatment failures (PO vs. IV) in those with definitive infection at baseline was
approximately 0.91, and the odds ratio for those with probable or possible infection was 0.56. Figure 4
shows that the CIs for both odds ratios cross 1. The results for the probable/possible infection subgroup
shows a lot of uncertainty owing to the small numbers included into this analysis.
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The overall interaction heterogeneity p-value is 0.531, indicating that there is no statistically significant
difference in the treatment effect between the subgroups.
Per-protocol analysis
A total of 909 participants were included in this subgroup analysis.
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FIGURE 4 Forest plot of OR (95% CI) for subgroup analyses (PO vs. IV). a, Baseline surgical procedure 1 (chronic
osteomyelitis debrided, no current implant or device or discitis/spinal osteomyelitis/epidural abscess debrided),
baseline surgical procedure 2 (chronic osteomyelitis as above, but not debrided or discitis/spinal osteomyelitis/
epidural abscess but not debrided), baseline surgical procedure 3 [implant or device present and retained (i.e. DAIR)],
baseline surgical procedure 4 (removal of orthopaedic device for infection or prosthetic joint implant removed)
and baseline surgical procedure 5 (prosthetic joint implant, one-stage revision); b, ad hoc subgroup analyses.
F/N, Failure/no failure.
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The odds ratio of definitive treatment failures (PO vs. IV) in those with definitive infection at baseline was
approximately 0.84, and the odds ratio for those with probable or possible infection was 0.56. CIs for both
odds ratios cross 1. The results for the probable/possible infection subgroup shows a lot of uncertainty
owing to the small numbers included into this analysis.
The overall interaction heterogeneity p-value is 0.612, indicating that there is no evidence that the
interaction between randomised treatment and the subgroups is statistically significantly different from 1.
Subgroup analysis of definite/probable versus possible infection at baseline
Modified intention-to-treat analysis analysis (complete-cases intention to treat)
Data for 1015 participants are included in this subgroup analysis.
The odds ratio of definitive treatment failures (PO vs. IV) in those with definitive or probable infection at
baseline was approximately 0.89, and the odds ratio for those with possible infection was 0.94. CIs for
both odds ratios cross 1. The results for the probable/possible infection subgroup shows a lot of
uncertainty owing to the small numbers included into this analysis.
The overall interaction heterogeneity p-value is 0.955, indicating that there is no evidence that the
interaction between randomised treatment and the subgroups is statistically significantly different from 1.
Per-protocol analysis
Data for 909 participants are included in this subgroup analysis.
The odds ratio of definitive treatment failures (PO vs. IV) in those with definitive or probable infection at
baseline was approximately 0.80, and the odds ratio for those with possible infection was 1.08. Results for
the probable/possible infection subgroup shows a lot of uncertainty owing to the small numbers included
into this analysis.
The overall interaction p-value is 0.782, indicating that there is no evidence that the interaction between
randomised treatment and the subgroups is statistically significantly different from 1.
Prespecified subgroup analysis considering the baseline surgical procedure
Subgroup analysis was used to determine the consistency of treatment effects by the baseline surgical
procedure. Information on the type of infection was collected at the enrolment of trial participants and
categorised as follows:
l baseline surgical procedure 1 – chronic osteomyelitis debrided, no current implant or device or discitis/
spinal osteomyelitis/epidural abscess debrided
l baseline surgical procedure 2 – chronic osteomyelitis as above, but not debrided or discitis/spinal
osteomyelitis/epidural abscess but not debrided
l baseline surgical procedure 3 – implant or device present and retained (i.e. DAIR)
l baseline surgical procedure 4 – removal of orthopaedic device for infection or prosthetic joint
implant removed
l baseline surgical procedure 5 – prosthetic joint implant, one-stage revision.
Results from a logistic regression model (ITT population) with the occurrence of the primary end point
(i.e. definite treatment failure as adjudicated by the blinded end-point review committee) as the outcome,
and the randomised treatment as well as the baseline surgical procedure (as a five-level categorical variable)
and the interaction between randomised treatment and baseline surgical procedure as explanatory variables
are presented.
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The interaction model does not indicate that any of the treatment/baseline surgical procedure interactions
are likely to be significant.
The overall interaction heterogeneity p-value is 0.263, indicating that there is no evidence that the
interaction between randomised treatment and the subgroups was statistically significantly different from 1.
In an additional post hoc subgroup analysis, restricted to metal retained versus not retained, we included
participants from the following baseline surgical procedure categories:
l No metal retained –
¢ chronic osteomyelitis debrided, no current implant or device
¢ removal of orthopaedic device for infection
¢ prosthetic joint implant removed.
l Metal retained –
¢ implant or device present and retained (i.e. DAIR)
¢ prosthetic joint implant, one-stage revision.
A total of 928 participants were included in this subgroup analysis.
The overall interaction heterogeneity p-value is 0.120, indicating that there is no evidence that the
interaction between randomised treatment and the subgroups was statistically significantly different from 1.
Prespecified subgroup analysis considering the infecting pathogen
Subgroup analysis was used to determine the consistency of treatment effects by infecting pathogen.
Information on the following five infecting pathogens, and if there was no pathogen, was collected:
1. S. aureus
2. Pseudomonas species
3. Gram-negative organism(s) (other than Pseudomonas)
4. Streptococcus species
5. coagulase negative Staphylococcus
6. no infecting pathogen identified.
When evidence for more than one of the above pathogens was present on the deep tissue microbiology
results taken prior to randomisation, they were assigned to the lowest numeric category in the above list.
The infecting pathogen was therefore a single variable with six levels.
The above categories for the infecting pathogens were chosen as part of a pragmatic approach and
included the main causative organism categories. It was felt that insufficient numbers of patients would be
available for other infecting pathogens to enable meaningful statistical subgroup analysis.
A total of 1015 participants (i.e. all participants with valid end-point data) were included in this summary.
Participants without an identified infecting pathogen were categorised as no infecting pathogen identified.
As no failures occurred in the PO arm of the Pseudomonas spp. subgroup, an odds ratio could not be
calculated for this group.
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The overall interaction heterogeneity p-value was 0.295, indicating that there is no evidence that the
interaction between randomised treatment and the subgroups was statistically significantly different from 1.
In the prespecified subgroup analysis, the point estimate suggests that IV therapy may confer an advantage
for patients in whom no infecting pathogen was identified.
Therefore, an additional post hoc analysis was performed to investigate the odds of definitive treatment
failure by treatment arm in participants with any pathogen compared with no pathogen identified.
The overall interaction heterogeneity p-value is 0.069, indicating that there is no evidence of an interaction
between randomised treatment and whether or not the pathogen was known.
Table 9 summarises the use of antibiotics according to whether the pathogen was known or unknown.
These data were available for 1011 participants.
This exploratory analysis demonstrates that in the IV arm, glycopeptides were the antibiotic category of
choice when the infecting pathogen was not identified.
Prespecified subgroup analysis considering the intended and actual
antibiotic choice
A subgroup analysis considered the clinician’s specific antibiotic intentions, as recorded prior to
randomisation, as a categorical variable. The antibiotic intentions were categorised into the following
groups based on the intended drug (Table 10). The rationale for this was to ensure that participants should
TABLE 9 Categorisation of antibiotics used (excluding rifampicin)
Antibiotics used
Antibiotics, n (%)
Total
(N= 1011),
n (%)
IV PO
Known
pathogen
(N= 391)
Unknown
pathogen
(N= 113)
Known
pathogen
(N= 396)
Unknown
pathogen
(N= 111)
Glycopeptides (IV) used 141 (36.06) 65 (57.52) 17 (4.29) 4 (3.60) 227 (22.45)
Penicillins (IV) used 27 (6.91) 7 (6.19) 5 (1.26) 3 (2.70) 42 (4.15)
Cephalosporins (IV) used 144 (36.83) 26 (23.01) 4 (1.01) 2 (1.80) 176 (17.41)
Carbapenems (IV) used 37 (9.46) 3 (2.65) 5 (1.26) 0 (0.00) 45 (4.45)
Other single IV antibiotic used 28 (7.16) 7 (6.19) 1 (0.25) 1 (0.90) 37 (3.66)
Combination IV antibiotics used 29 (7.42) 6 (5.31) 5 (1.26) 1 (0.90) 41 (4.06)
Penicillins (PO) used 7 (1.79) 1 (0.88) 61 (15.40) 20 (18.02) 89 (8.80)
Quinolones (PO) used 24 (6.14) 7 (6.19) 146 (36.87) 39 (35.14) 216 (21.36)
Tetracyclines (PO) used 1 (0.26) 3 (2.65) 44 (11.11) 11 (9.91) 59 (5.84)
Macrolides/lincosamide (PO) used 7 (1.79) 3 (2.65) 51 (12.88) 15 (13.51) 76 (7.52)
Other single PO antibiotic (PO) used 5 (1.28) 5 (4.42) 42 (10.61) 11 (9.91) 63 (6.23)
Combination PO antibiotics (PO) used 6 (1.53) 5 (4.42) 65 (16.41) 19 (17.12) 95 (9.40)
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have options for both IV therapy and PO therapy, thus demonstrating true equipoise from the infection
specialist over the effectiveness of the two trial arms at the point of randomisation.
The results of the logistic regression models using the occurrence of the primary end points (i.e. definite
treatment failure as adjudicated by the blinded end-point review committee) as the outcome, and the
randomised treatment as well as the subcategory of the antibiotic intention and the interaction between the
two variables are displayed below. Separate analyses are shown for the planned IV and planned PO treatments.
Intravenous and PO intentions were not documented for all participants, as it was not a requirement in the
initial single-centre pilot study. Only those participants of the MITT population with available IV and PO
plans were included into these analyses (913 participants).
Planned intravenous treatments
Of the 917 participants for whom relevant data were available, 380 were planned to receive glycopeptides
if randomised to IV therapy. Of these, 216 were subsequently randomised to IV therapy and 164 were
randomised to PO therapy. The asymmetry between the arms for missing data might suggest that these
data fields were not reliably completed prior to randomisation.
The overall interaction heterogeneity p-value is 0.416, indicating that there is no evidence that the
interaction between randomised treatment and the subgroups was statistically significantly different
from 1.
Planned oral treatments
Of the 945 participants for whom relevant data were available, 131 were planned to receive penicillins
if randomised to PO therapy. Of these, 57 were subsequently randomised to IV therapy and 74 were
randomised to PO therapy. The asymmetry between the arms for missing data might suggest that these
data fields were not reliably completed prior to randomisation.
The overall interaction p-value is 0.800, indicating that there is no evidence that the interaction between
randomised treatment and the subgroups is statistically significantly different from 1.
Inclusion of rifampicin into the planned intravenous and oral choices
According to the available data, adjunctive rifampicin was included in the planned IV regimen in
142 partipants. Of these, 73 were subsequently randomised to IV therapy and 69 were randomised to PO
therapy. The overall interaction heterogeneity p-value is 0.876, indicating that there was no evidence that
the interaction between randomised treatment and the subgroups is statistically significantly different from 1.
TABLE 10 Categorisation of planned IV and PO treatments
Treatments
Planned IV Planned PO
1. Glycopeptides (i.e. teicoplanin/vancomycin)
2. Penicillins
3. Cephalosporins
4. Carbapenems
5. Other single IV antibiotic
6. Combination IV antibiotics
1. Penicillins
2. Quinolones
3. Tetracyclines
4. Macrolides/Lincosamide
5. Other single PO antibiotic
6. Combination PO antibiotics
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Rifampicin was included in the planned PO regimen in 487 participants. Of these, 228 were subsequently
randomised to IV therapy and 259 were randomised to PO therapy.
The overall interaction heterogeneity p-value is 0.122, indicating that there is no evidence that the
interaction between randomised treatment and the subgroups was statistically significantly different from 1.
Treatment by peripheral vascular disease interaction
A final post hoc subgroup analysis looked at the effect of peripheral vascular disease as recorded at
randomisation. This factor was identified as being associated with the outcome in the adjusted logistic
regression analysis performed as part of the supporting analyses.
A total of 1015 participants (i.e. all participants with valid end-point data) were included in this summary.
The overall interaction heterogeneity p-value is 0.467, indicating that there was no evidence of an
interaction between randomised treatment and whether or not peripheral vascular disease was present.
Adverse events and complications
Clostridium difficile
Summaries for episodes of C. difficile include all participants for whom at least one follow-up assessment
was entered onto the database (Table 11).
Information on C. difficile was collected on the day 42 and day 120 CRFs. Day 42 forms were received for
1046 participants; all were included in this analysis. The day 120 form was received for a subset of
these participants.
C. difficile data were missing for three participants: two in the IV arm and one in the PO arm. Two of
these participants were withdrawn prior to their day 42 follow-up, and one died; therefore, the relevant
information was not available for these participants (risk difference –0.8%, 95% CI –2.2% to 0.6%).
Using all participants with non-missing data (MITT population, n = 1043), there was no evidence of an
association between randomised strategy and the occurrence of episodes of C. difficile (p-value = 0.298,
using Fisher’s exact test).
Serious adverse events
All reported and confirmed SAEs were included in the summaries reported in Tables 12 and 13.
Table 14 shows details for the SAEs reported in relation to randomisation.
TABLE 11 Summary of episodes of C. difficile
Episode
Antibiotic
Total (n= 1046)IV (n= 523) PO (n= 523)
Episode of C. difficilea 9 (1.72) 5 (0.96) 14 (1.34)
a Frequency and percentages are displayed.
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TABLE 12 Summary of patients with at least one recorded SAE and the number of reported SAEs per participant
SAEs
Antibiotic
Total (n= 1046)IV (n= 527) PO (n= 527)
SAE reporteda 146 (27.70) 138 (26.19) 284 (26.94)
Number of SAEs reporteda
0 381 (72.30) 389 (73.81) 770 (73.06)
1 109 (20.68) 89 (16.89) 198 (18.79)
2 20 (3.80) 29 (5.50) 49 (4.65)
3 9 (1.71) 7 (1.33) 16 (1.52)
4 4 (0.76) 10 (1.90) 14 (1.33)
5 1 (0.19) 2 (0.38) 3 (0.28)
6 2 (0.38) 1 (0.19) 3 (0.28)
11 1 (0.19) 0 (0.00) 1 (0.09)
a Frequency and percentages are displayed.
TABLE 13 Summary of SAE information
SAE information
Antibiotic
Total (n= 444)IV (n= 220) PO (n= 224)
Timing of SAE onset from randomisation (in weeks)a 18 (4, 36), (0, 57) 16 (4, 35), (0, 56) 17 (4, 35), (0, 57)
SAE expecteda
Yesb 220 (100.00%) 224 (100.00%) 444 (100.00%)
SAE related to randomised interventiona
No 218 (99.09%) 220 (98.21%) 438 (98.65%)
Yes 2 (0.91%) 4 (1.79%) 6 (1.35%)
SAE outcomea
Resolved 154 (70.00%) 172 (76.79%) 326 (73.42%)
Ongoingc 10 (4.55%) 19 (8.48%) 29 (6.53%)
Resolved with sequelae 39 (17.73%) 27 (12.05%) 66 (14.86%)
Death 17 (7.73%) 6 (2.68%) 23 (5.18%)
SAE severitya
Mild 56 (25.45%) 43 (19.20%) 99 (22.30%)
Moderate 119 (54.09%) 123 (54.91%) 242 (54.50%)
Severe 45 (20.45%) 58 (25.89%) 103 (23.20%)
a Frequency and percentages are displayed.
b There were no SAEs that were unexpected in accordance with the protocol definition.
c A total of 29 SAEs are marked as ‘ongoing’. Of these, 12 were related to underlying chronic medical conditions (diabetic
foot ulcers, n= 6; neoplasms, n= 3; rheumatoid arthritis, n= 1; ischaemic heart disease, n= 1; pressure ulcers in spina
bifida, n= 1) and 12 episodes were eventually resolved following definitive treatment (deep-vein thrombosis, n= 2; RTA with
fracture, n= 1; wound issues/recurrent dislocations leading eventually to surgery, n= 9). One SAE was still ongoing beyond
the 1-year follow-up. Four SAEs were likely to have resolved by the time of discharge and were probably misclassified.
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The frequency of line complications
The following summaries refer primarily to participants randomised to the IV strategy; therefore, no
statistical tests were performed (Table 15).
Information on line complications was collected on the day 42 and day 120 CRFs. Day 42 forms were
received for 1046 participants and these are all included in Table 15. The day 120 form was received for a
subset of these participants.
Information on line complications was missing for three participants: two in the IV arm and one in the PO
arm. Two of these participants were withdrawn prior to their day 42 follow-up, and one died; therefore,
the relevant information is not available for these participants.
Five line complications were reported in the PO arm of the trial. Of these, four related to participants who
exited early from their allocated treatment strategy and were treated with IV therapy. One further line
complication in the PO arm arose in relation to a planned second stage procedure, which took place after
the completion of the 6 weeks’ randomised strategy.
TABLE 14 Summary of SAE information for events related to the randomisation
ID
number
Randomised
treatment
Date of SAE description as
documented on the trial
database Outcome
Timing
(weeks)Randomisation SAE onset
2113 PO 22 October 2013 30 October 2013 Admitted with nausea and
vomiting. Had brief break
from PO ciprofloxacin,
which was then restarted
Resolved 1
2386 PO 1 July 2014 6 July 2014 Diarrhoea, nausea,
vomiting and exhaustion
associated with (liquid) PO
antibiotics. Admitted for
symptomatic therapy and
switched to IV ceftriaxone
Resolved 0
2664a PO 1 May 2015 24 June 2015 Left arm swelling
investigated for midline
infection; no infection or
line complication found
Resolved 7
2694b IV 11 June 2015 16 August 2015 Reaction to doxycycline:
burning lower leg and
blisters on feet.
Widespread pruritus
Resolved
with
sequelae
9
2701c IV 17 June 2015 26 June 2015 Severe oesophagitis
thought to be attributable
to PO antibiotics
Resolved 1
2796 PO 18 September 2015 22 September 2015 Participant had an
unplanned admission
as a result of intolerance of
PO antibiotics. Symptoms
were loose stools and
a reduction in the
effectiveness of the
participant’s methadone
Resolved 0
ID, identification.
a This participant exited early from their randomised strategy and received IV treatment.
b This SAE occurred during follow-up treatment (i.e. after completion of the randomised strategy).
c This participant received adjunctive PO therapy to which the SAE was ascribed.
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Early termination of the planned 6-week strategy
Information on early termination from the allocated treatment strategy was collected on the day 42 and
day 120 CRFs.
A total of 1046 participants had at least one of these forms available, and they are included in the
following summaries (Table 16).
Information on early exits was missing for three participants. Two of these were withdrawn prior to their
day 42 follow-up and one died; therefore, the relevant information was not available for these participants.
Pearson’s chi-squared test (H0: no association between treatment and early exit) suggests that there was
evidence of an association between randomised treatment arm and early exit from the allocated
strategy (p = 0.006).
Quality of life evaluated by the EuroQol-5 Dimensions, three-level
version questionnaire
The EQ-5D-3L index ranges from –0.594 to 1, with higher values indicating better health states and zero
indicating a health state equivalent to death.
TABLE 15 Summary of line complications
Line complications
Antibiotic
Total (n= 1046a)IV (n= 523) PO (n= 523)
IV line detailsb
Not present 64 (12.24) 489 (93.50) 553 (52.87)
PICC 450 (86.04) 30 (5.74)c 480 (45.89)
Hickman 5 (0.96) 1 (0.19) 6 (0.57)
Otherd 2 (0.38) 2 (0.38) 4 (0.38)
Missing 2 (0.38) 1 (0.19) 3 (0.29)
Line complicationsb 49 (9.37) 5 (0.96) 54 (5.16)
Nature of line complicationsb (n = 49) (n = 5e) (n = 54)
Mechanical failure 24 (48.98) 3 (60.00) 27 (50.00)
Thrombophlebitis/thrombosis 13 (26.53) 1 (20.00) 14 (25.93)
Infection 12 (24.49) 1 (20.00) 13 (24.07)
Line removed as result of line complicationsb (n = 49) (n = 5e) (n = 54)
Yes 42 (85.71) 4 (80.00) 46 (85.19)
Replacement of line after removal (n = 42) (n = 4) (n = 46)
Yes 18 (42.86) 4 (100.00) 22 (47.83)
PICC, peripherally inserted central catheter.
a Number of day 42 forms received.
b Frequency and percentages are displayed.
c The majority of these participants were early exits from their randomised strategy.
d The ‘other’ IV lines consisted of three peripheral cannulas, and one particant had an IV line for haemodialysis.
e Five incidences of line complications were reported in the PO arm of the trial. Four of these line complications occurred
within the initial 6 weeks of treatment in participants who had exited early from their allocated PO strategy and were
using IV treatments. The remaining line complication occurred beyond the initial 6 weeks of treatment.
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The EQ-5D VAS ranges from 0 to 100, with higher values indicating better health states.
The results for the quantile regression on the EQ-5D-3L index and VAS showed no evidence of an effect of
randomised strategy on the median outcome at any of the follow-up time points.
The quantile regression models were adjusted for a number of covariates, as outlined in the statistical
analysis plan. The covariate adjustment aimed to separate the effect of the randomised intervention from
other factors which may also have an influence on the EQ-5D-3L and EQ-5D VAS at follow-up.
Similarly, there was no evidence of an effect of randomised strategy on the median OHS outcomes at
any follow-up time point. However, there was evidence to suggest that the randomised strategy has a
statistically significant effect on the median outcome of the OKS at both the day 120 and day 365
follow-up in favour of PO therapy.
The quantile regression models were adjusted for a number of covariates, as outlined in the statistical
analysis plan. The covariate adjustment aimed to separate the effect of the randomised intervention from
other factors that may also have had an influence on the OHS and OKS at follow-up.
Adherence to oral medication
The MEMS was used in a subset of sites (Oxford University Hospitals, Guy’s and St. Thomas’ Hospitals,
Royal Free London and Royal National Orthopaedic Hospital). MEMS caps were returned by 63 participants
allocated to the PO arm. Compliance with PO therapy at 42 days according to MEMS data ranged from
45% to 100%.
TABLE 16 Early termination from allocated strategy by treatment arm
Reasons for early exit from allocated
treatment strategya
Antibiotic
Total
[166/1046 (15.87%)]IV [99/523 (18.93%)] PO [67/523 (12.81%)]
Intolerance 26 (26.26) 23 (34.33) 49 (29.52)
Patient preference 19 (19.19) 5 (7.46) 24 (14.46)
Difficulties with IV access or administration 41 (41.41) 0 (0.00) 41 (24.70)
Intercurrent illness 2 (2.02) 8 (11.94) 10 (6.02)
Due to possible or probable recurrenceb 1 (1.01) 15 (22.39) 16 (9.64)
Good clinical response 1 (1.01) 0 (0.00) 1 (0.60)
Otherc 9 (9.09) 15 (22.39) 24 (14.46)
Reason not available 0 (0.00) 1 (1.49) 1 (0.60)
a Frequency and percentages are displayed.
b The participant in the IV arm was found to have a definitive treatment failure and their treatment was discontinued in
preparation for further surgery. A total of 11 out of 15 participants in the PO arm were found to have a definitive failure,
the remaining four did not have a definitive failure. In all cases, the participant was either switched to IV therapy, because
of concern about possible therapeutic failure, or antimicrobials were stopped in preparation for surgery.
c Other reasons for early exit include:
• prescription changed by a clinician who was not involved in the OVIVA study (four PO and four IV participants)
• infection status was unclear and the clinicians decided that the participants did not need prolonged antibiotics
(four PO and three IV participants)
• no PO option was available (six PO participants)
• early exit as clinician required particular antibiotic regimen to cover possibility of exotic organism (one IV participant)
• early exit because of poor compliance on PO medication (one PO participant)
• early exit linked to death (one IV participant).
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Antibacterial agents used for treatment
This section presents data on the antibiotic regimens received by participants during the first 42 days of
the trial.
Data for 1044 participants were available for these summaries (Table 17). No antibiotic data were available
for five trial participants and, for an additional five participants, insufficient antibiotic information was
available to categorise their antibiotic regimen.
The categories in this table were not mutually exclusive; participants could fall into more than one
category. A total of 145 participants fell into two antibiotic categories, three participants fell into three
categories and one participant fell into four categories.
All participants in the PO arm who received IV antibiotics were early exits from their randomised strategy.
All participants in the IV arm who received PO antibiotics were early exits from their randomised strategy or
were on adjunctive PO therapy.
Figure 5 shows the proportion of participants on IV antibiotic therapy on each day from the start of
treatment episode through to day 60, by treatment arm. As expected according to the trial protocol, the
figure shows a marked decline in IV use around day 7 in the PO arm and around day 42 in the IV arm.
Participants who were randomised to PO therapy but were receiving IV therapy after day 7 represent either
early exits from strategy, permissible short-term IV therapy for concomittant illness or, in seven cases,
protocol deviation. Two further apparent protocol deviations were likely to be a result of data entry error.
The number of patients continuing long-term antibiotic treatment (after 6 weeks) and time to permanent
discontinuation of all antibiotic treatment (defined as the first day when antibiotics are not taken for the
next 14 days) are displayed in Table 18 and Figure 6. Antibiotic use was capped at 400 days when use was
recoded beyond that period.
Using the Wilcoxon rank-sum test, there was no evidence of effect of randomised strategy on the median
long-term use of antibiotics between the treatment arms (p = 0.628).
TABLE 17 Overview of actual antibiotic regimens
Antibiotic regimena
Antibiotic
Total (n= 1044)IV (n= 521) PO (n= 523)
Glycopeptides (IV) used 214 (41.07) 22 (4.21) 236 (22.61)
Penicillins (IV) used 38 (7.29) 11 (2.10) 49 (4.69)
Cephalosporins (IV) used 173 (33.21) 8 (1.53) 181 (17.34)
Carbapenems (IV) used 41 (7.87) 5 (0.96) 46 (4.41)
Other single IV antibiotic used 35 (6.72) 2 (0.38) 37 (3.54)
Combination IV antibiotics used 35 (6.72) 6 (1.15) 41 (3.93)
Penicillins (PO) used 8 (1.54) 83 (15.87) 91 (8.72)
Quinolones (PO) used 33 (6.33) 191 (36.52) 224 (21.46)
Tetracyclines (PO) used 4 (0.77) 57 (10.90) 61 (5.84)
Macrolides/lincosamide (PO) used 10 (1.92) 68 (13.00) 78 (7.47)
Other single PO antibiotic used 10 (1.92) 54 (10.33) 64 (6.13)
Combination PO antibiotics used 13 (2.50) 87 (16.63) 100 (9.58)
a Frequency and percentages are displayed.
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TABLE 18 Long-term use of antibiotics
Long-term use
Antibiotic
Total (n= 1049)IV (n= 523) PO (n= 526)
Antibiotic treatment continued beyond 6 weeksa
No 139 (26.58) 125 (23.76) 264 (25.17)
Yes 384 (73.42) 401 (76.24) 785 (74.83)
Duration of antibiotic useb 78 (42–99) (1–400) 71 (43–94) (2–400) 76 (42–96) (1–400)
a Frequency and percentages are displayed.
b Median, interquartile range and range are displayed.
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Agreement between intended and received antibiotics
This section presents agreements between the planned PO and IV antibiotics as stated prior to
randomisation and actual antibiotic administered. Included in the summaries are participants for whom
both the intended and actual antibiotic choices were available (Table 19). For one participant, the
information provided was insufficient for categorisation.
Summaries are categorised as follows.
l Full match: received their randomised strategy and remained within the intended antibiotic group.
l Partial match: received their randomised strategy but deviated from the intended antibiotic group.
l No match: received < 50% of planned therapy within randomised strategy.
Note that the definition for the ‘no match’ category is different from that in the approved statistical
analysis plan (version 2.0). Originally, this category was defined as ‘early exit from randomised strategy’.
The updated definition was felt to be more accurate and clinically relevant.
Duration of primary hospital stay
Time from randomisation to discharge is summarised in Figure 7. This summary excludes participants who
were treated as outpatients (length of stay of zero) and those who died during their initial hospital stay.
Note that readmission post discharge was recorded as a SAE and represented a secondary end point.
TABLE 19 Compliance with intended antibiotics as stated prior to randomisation
Compliancea
Antibiotic
Total (n= 1044)IV (n= 521) PO (n= 523)
Complete match 370 (71.02) 374 (71.51) 744 (71.26)
Partial match 68 (13.05) 90 (17.21) 158 (15.13)
No match 83 (15.93) 58 (11.09) 141 (13.51)
Missingb 0 (0.00) 1 (0.19) 1 (0.10)
a Frequency and percentages are displayed.
b For one participant, insufficient data had been provided to perform the matching.
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Using the Wilcoxon rank-sum test, there is sufficient evidence to suggest a difference in the median time
from randomisation to discharge between the treatment arms (p < 0.001).
Results of health economics analysis
Results from the trial indicate that PO antibiotics are non-inferior to IV antibiotics. Results are presented for
complete cases as well as using the ITT population, for which missing values were replaced using
imputation methods.
Missing data
The effects of missing data were explored using both mean and multiple imputation. Missing cost values
were replaced at the aggregate total cost level using both mean imputation and multiple imputation.
Missing quality-of-life data were replaced at utility score level at each EQ-5D-3L follow-up point using
multiple imputation.
Resource use
Only a small proportion of patients had missing resource use data (IV arm, n = 12; PO arm, n = 14).
Table 20 shows data, for any indication, from incident admission through to 1 year of follow-up for the
mean number of antibiotic prescriptions, antibiotic duration in days, mean number of inpatient admissions,
the mean length of stay as inpatient and the total number of days that a patient received IV therapy. The
antibiotic duration sums the duration of all antibiotic use, including simultaneous use. The IV duration
includes the length of IV episodes for which an IV line was needed to administer IV antibiotics (including
more than one IV antibiotic taken at the same time as another).
There were no statistically significant differences between arms for antibiotic prescriptions and duration,
number of inpatient stays or total inpatient duration over 1 year. However, there was a statistically
significant difference in the mean number of days’ IV therapy was received. On average, the total number
of days that IV therapy was received was 34.62 days longer in the IV arm than in the PO arm. Table 21
presents the mean costs in both arms for unadjusted complete cases.
For unadjusted complete cases, the total mean non-surgical cost was £13,275 in the IV arm compared with
£10,549 in the PO arm. The observed difference in mean total cost between arms was £2727, a statistically
significant result. The mean cost differences for antibiotics and IV costs were also statistically significant, but
there was no statistically significant difference in inpatient costs between the IV and PO arm over 1 year.
TABLE 20 Resource use per participant (complete case)
Resource type
Antibiotic
Difference 95% CI
IV PO
Mean (SD) n (%) Mean (SD) n (%)
Number of antibiotic
prescriptions
6.70 (3.74) 515 (97.7) 6.43 (3.93) 513 (97.3) 0.276 –0.19 to 0.74
Antibiotic duration (days) 189.8 (177.5) 515 (97.7) 185.6 (156.3) 513 (97.3) 4.18 –16.29 to 24.65
Number of inpatient
admissions
1.83 (1.15) 515 (97.7) 1.82 (1.11) 513 (97.3) 0.01 –0.12 to 0.14
Inpatient duration (days) 26.22 (24.28) 515 (97.7) 26.35 (28.47) 513 (97.3) –0.125 –3.36 to 3.11
Total number of days IV
therapy was received
52.58 (40.37) 515 (97.7) 17.96 (33.52) 513 (97.3) 34.62 30.08 to 39.16
SD, standard deviation.
Reproduced with permission from McMeekin et al.29 © 2019 McMeekin et al. This is an open access article distributed
under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
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To explore the difference in costs between IV and PO antibiotics for a 42-day course, trial results were
used to calculate the mean daily cost of all antibiotics in each arm. The mean cost of a 42-day (6-week)
course of antibiotics (antibiotics only) was £997 [standard deviation (SD) £873] for IV antibiotics and £188
(SD £648) for PO antibiotics.
Health outcomes: quality-adjusted life-years
The proportion of available data for each EQ-5D-3L questionnaire is presented in Table 22. These values
include zero utility scores after death for deceased participants.
The complete-case EQ-5D-3L questionnaire results at dimension level showed that, in all domains, there
was a lower proportion of participants in levels 2 and 3 at the 365-day follow-up than earlier follow-ups.
This indicated that there was improvement in all aspects of the EQ-5D-3L from mobility through to anxiety,
and this was seen in both the IV and PO arms.
The data for mean EQ-5D-3L utilities at baseline and at 14, 42, 120 and 365 days, along with mean
QALYs, showed that there were no statistically significant differences in mean utilities at any follow-up
point or in mean QALYs. Results consider a zero utility score for patients who died during the trial.29
The utilities in both arms improved at each follow-up point compared with the previous follow-up point.
Available data percentages ranged from 73.6% at baseline to 54.3% at the 365-day follow-up.
TABLE 21 Unadjusted base-case costs (complete case)
Cost category
Antibiotics
Difference 95% CI p-value
IV PO
Mean (SD) n (%) Mean (SD) n (%)
Antibiotics £1992
(£2545)
515
(97.7)
£1207
(£2043)
513
(97.3)
£785 £502 to £1067 < 0.01
Inpatient stays £7756
(£7183)
515
(97.7)
£7793
(£8420)
513
(97.3)
–£37 –£995 to 920 0.94
IV costs £3527
(£2920)
515
(97.7)
£1548
(£1618)
513
(97.3)
£1979 £1690 to £2268 < 0.01
Total costs (excluding
surgical costs)
£13,275
(£10,113)
515
(97.7)
£10,549
(10,371)
513
(97.3)
£2727 £1473 to £3980 < 0.01
SD, standard deviation.
Reproduced with permission from McMeekin et al.29 © 2019 McMeekin et al. This is an open access article distributed
under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
TABLE 22 Proportion of participants with available EQ-5D-3L score data
Time point
Antibiotic
IV (%) PO (%)
Baseline 73.2 73.6
14 days 58.4 58.6
6 weeks 69.4 71.0
4 months 59.2 58.1
12 months 57.1 54.3
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Imputation results
Mean and multiple imputation was carried out for total costs and are presented in Table 23.
Results for both mean and multiple imputation were consistent with the results from the base-case
complete-case analysis; the mean cost differences for mean and multiple imputations were £2735 and
£2740, respectively, compared with £2727 for complete-case analysis. All of these results showed a
statistically significant difference between arms. The results of the multiple imputation for QALYs show a
difference of –0.007 between arms, compared with 0.023 for complete cases. Neither of these results
were statistically significant.
Sensitivity analysis
The results of the sensitivity analysis were similar to the base-case results, with a difference in total costs
between arms of £2617–2887, compared with £2727 in the complete-case results.
Cost-effectiveness
Mean costs were observed to be lower in the PO arm and mean QALYs were higher in the PO arm than the
IV arm, suggesting that the strategy of treating bone and joint infections with PO antibiotics is a dominant
strategy. However, there is uncertainty surrounding this result, which is explored further in the next section.
Uncertainty
Although the difference in costs between strategies was found to be statistically significant, there is
uncertainty around the magnitude of this difference and we can be 95% confident that this difference
is between £1488 and £3992. The difference between QALYs is not statistically significant and results
suggest that we can be 95% confident that the real difference in total QALYs between treatment arms is
between –0.045 and 0.031 and, therefore, favours neither strategy.
Figure 8 shows the cost-effectiveness plane with 1000 bootstrap samples of the ICER. It also shows a point
estimate giving the mean differences in costs and QALYs between treatment arms. This figure also includes
a line showing the £30,000 threshold currently used to assess cost-effectiveness by National Institute for
Health and Care Excellence (NICE), and the lower and upper 95% CI from the bootstrap samples.35 All
bootstrap samples had a lower cost in the PO arm than the IV arm, and most (82.8%) of cost-effectiveness
pairs are in the south-east quadrant. In this quadrant, lower costs and higher QALYs can be observed for
the PO arm as compared with the IV arm, which makes a PO intervention dominant for these samples.29
However, some samples fall into the south-west quadrant of the plane, where patients in the PO arm have
fewer QALYs than patients in the IV arm. Similar to observed cost-effectiveness results, non-parametric
bootstrapping also resulted in a negative ICER of –£108,500, indicating that the PO strategy was dominant,
TABLE 23 Mean and multiple imputation results
Total costs
Antibiotic (mean costs)
Difference (SE) 95% CIIV PO
Mean imputation results
Total costs £13,141 (SD £10,036) £10,406 (SD £10,269) £2735 (£625) £1508 to £3963
Multiple imputation results
Total costs £13,274 (SE £446) £10,534 (SE £453) £2740 (£638) £1488 to £3992
Total QALYs 0.537 (SE 0.013) 0.545 (SE 0.015) –0.007 (0.019) –0.05 to 0.03
SE, standard error.
Reproduced with permission from McMeekin et al.29 © 2019 McMeekin et al. This is an open access article distributed
under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
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with the 95% CI ranging from –£1,592,000 to £1,126,000. The mean cost difference was £2924 (standard
error £1031) in favour of the PO strategy, and mean QALYs were 0.027 (standard error 0.031) in favour
of the PO strategy. The lower 95% CI line indicates that there is a possibility that the true difference in
QALYs may be in the south-west quadrant. When the IV intervention results in higher QALYs than the PO
intervention, there is uncertainty that the PO arm dominates; 17.2% of the bootstrap samples fall in the
south-west quadrant, where the IV strategy is less costly but also results in higher QALYs. The strategy of
treating bone and joint infections with PO antibiotics is dominant in the lower limit of the 95% CI, and it is
also dominant in the point estimate of the ICER and has an upper limit of £1,126,000 per QALY gained.
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FIGURE 8 Cost-effectiveness plane. Reproduced with permission from McMeekin et al.29 © 2019 McMeekin et al.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Chapter 4 Discussion
Some of the material in this chapter has previously been published in our description of the trial,reproduced from Li et al.1 This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes
were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Despite a widely held view that the successful management of bone and joint infection requires IV
rather than PO antibiotics,38–40 there is no evidence to suggest that PO antibiotic therapy results in worse
outcomes. Nonetheless, there is significant variation in practice, with some centres advocating prolonged
courses of IV therapy, some using short courses of IV therapy and others relying primarily on locally
administered antibiotic agents.41,42 Such lack of consensus demonstrates that the current trial addresses
an important question and that the results are likely to influence practice. This is reflected in a study43
in which 500 infectious diseases physicians were asked to prioritise more than 100 research questions
relating to infection. Four out of the top five responses related to route of administration of antibiotics
and the top two concerned orthopaedic infection specifically.
The aim of the trial was to determine whether or not PO antibiotic therapy is non-inferior to IV antibiotic
therapy when used for the first 6 weeks in the treatment of bone and joint infection. All recruiting centres
routinely used a 6-week course of IV therapy for some or all bone and joint infections as their standard
care pathway.
The results of the OVIVA trial demonstrate that PO therapy, when used during the initial 6 weeks in the
treatment in bone and joint infection, is non-inferior to IV therapy. This finding held true for the ITT
analysis, the complete-case analysis (which excluded participants for whom no valid end-point data were
available), the PP analysis (defined by participants who received at least 4 weeks of their allocated
treatment strategy or who exited early owing to potential treatment failure) and for sensitivity analyses
(which substituted missing primary end points with the most extreme possible outcomes).
A secondary analysis, which included 16 possible and probable treatment failures as composites with
definitive treatment failure, also demonstrated non-inferiority of PO therapy as compared with IV therapy.
Predefined subgroup analyses focusing on diagnostic certainty at baseline, surgical procedure, bacterial
pathogen, trial site and planned IV or PO antibiotic regimen at the time of randomisation showed no
evidence of a differential effect of either treatment arm. Similarly, post hoc analyses relating to retention
of metalware, peripheral vascular disease and culture-negative infection demonstrated no advantage of
IV over PO therapy. For a pragmatic and unselective trial, with significant heterogeneity in the population
under study, the findings from these subgroup analyses are reassuring and, overall, suggest that the results
from this trial can reasonably be assumed to be broadly generalisable. However, none was sufficiently
powered formally to compare outcomes following IV and PO therapy and, although we believe that we
selected the most important subgroups for analysis, we cannot exclude the possibility that there are
otherwise unidentified subgroups for whom IV (or PO) therapy may be superior.
Adverse events and complications
For the purposes of this trial, C. difficile diarrhoea and complications relating to IV access devices (or lines)
were analysed as secondary end points rather than SAEs.
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As expected, line complications were significantly more common among participants randomised to
IV therapy. Although the incidence was relatively modest, the mortality associated with line infection in
particular has been reported at 12–25%.44 Elimination of this risk by using PO therapy may therefore offer
considerable advantage and, extrapolating from the presumed incidence data that we used to inform the
design of the OVIVA trial, could avert 19–40 deaths annually in the UK.
The incidence of C. difficle diarrhoea and SAEs did not differ significantly between the treatment arms.
A total of 23 patients died during the conduct of the study but none was considered related to the
randomised strategy.
Patient-reported outcome measures
Data collection for the EQ-5D-3L was suboptimal. Although we cannot be certain that the missing data
arose randomly, the trial showed no evidence that randomised strategy had any effect on the EQ-5D index
at any time point.
The OHS and OKS were originally designed as assessment tools to indicate whether or not patients may
have reached a threshold for joint replacement.45,46 Although not necessarily directly applicable to the
population included in this trial, they have been validated as research tools. We therefore collected the data
as part of an assessment of functional outcome. For the OHS, the unadjusted scores indicated a difference
between the trial arms at 120 and 365 days in favour of IV therapy, but in an adjusted quantile regression
model there was insufficient evidence to suggest that the randomised strategy had a statistically significant
effect on the median outcome at any time point. For the OKS, unadjusted scores indicated a difference
between the trial arms at 120 and 365 days in favour of PO therapy, and the adjusted quantile regression
model amplified this difference, which was statistically significant at both time points. A plausible biological
explanation for this is lacking but it is possible that the difference between the adjusted and unadjusted
estimates is attributable to the fact that only a small subgroup of the population is included in either the
OHS or OKS sample.
There was clear evidence of improvement over time in all elements of the EQ-5D, and in the OHS and OKS,
in both arms of the trial. This suggests that patients’ mobility, self-care, activity level, pain, psychological
status and joint function generally improved progressively following the start of treatment for their incident
bone or joint infection.
Adherence to medication
At the outset of this trial, we were concerned that if PO therapy proved inferior to IV therapy, this might
have arisen as a result of ‘failure of compliance with oral therapy’ rather than ‘therapeutic failure of oral
antibiotics’. To address this concern, we issued very clear guidance on the importance of adherence, both
verbally and in writing, at the time of randomisation. We did not subsequently provide direct adherence
support, such as text reminders, as this would be difficult to translate into routine practice.
Follow-on antibiotic therapy
The total duration of treatment, including follow-on therapy after the initial 6 weeks of treatment, is usually
determined by a combination of factors such as the presence or absence of metalware, the organism
isolated, the certainty with which all non-vital tissue has been excised and the availability of options for
further surgical intervention should an infection recur. Previous studies have shown that timing of recurrence
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of infection is commonly related to the cessation of antibiotic therapy.47 In this open-label trial, we were
concerned that clinicians might inadvertently (or deliberately) extend follow-on therapy for participants who
had been randomised to the PO arm. Therefore, we analysed the total duration of therapy in all participants.
The results demonstrated no evidence of prolongation of follow-on therapy in one or other arm of the trial.
There were clear indicators that the proportion of participants remaining on therapy fell markedly at 6 weeks,
3 months, 6 months and 1 year. Although these time points reflect clinical practice, they probably represent
digit preference rather than an evidence base governing total duration of therapy. It suggests that significant
redundancy may be built into our current practice; if so, there could be considerable gains in terms of cost
and antibiotic minimisation if optimal duration of therapy could be more clearly defined prospectively.
Health economics
As the results of the trial indicate that PO antibiotics are non-inferior to IV antibiotics, there is no possibility
of incremental benefit in outcomes of one treatment over the other. Therefore, it was not considered
necessary or useful to carry out a full economic evaluation. The results of the EQ-5D-3L questionnaires
reflected the main trial outcome of definitive failures; there was no statistically significant difference in
the QALYs between arms.29 This was reinforced by post hoc regression of QALYs on ‘definite failure’, for
which the indicator variable for failure was found to be statistically significant, confirming that the EQ-5D
measure is sensitive to the end point. However, the end point was found not to differ between arms.
The difference in costs between arms was £2740 using multiple imputation, indicating that the use of PO
antibiotics to treat a bone or joint infection was significantly cheaper (when taking into account the cost
of antibiotics, IV administration and inpatient stays over the course of 1 year) than the use of IV antibiotics.
With PO antibiotics being non-inferior to IV administration, and the costs in the PO arm being significantly
less than the IV arm during the trial, the results suggest that the PO arm was a dominant strategy.
However, there was uncertainty around these results. Although there was no statistical difference in the
QALYs, and PO antibiotics were found to be non-inferior to IV antibiotics using the primary outcome, the
uncertainty around the economic results was explored further. These results suggested that, although in
82.8% of the bootstrap sample the PO strategy is dominant, 17.2% of the samples indicated that the IV
strategy would result in higher QALYs than the PO strategy and still at a higher cost. However, at the NICE
willingness-to-pay threshold of £30,000 there was a 100% probability of the PO intervention being more
cost-effective than the IV intervention.
Despite the economic burden of bone and joint infection, economic studies in this area are rare.48 A
cost-effectiveness study that compared exchange arthroplasty with debridement and prosthetic retention for
infected total hip arthroplasty in the elderly found that retention and debridement improved quality-adjusted
life expectancy and also increased costs in 65- and 80-year-old men and women over a lifetime.49 The ICER
ranged from US$500 for frail 80-year-old men to US$21,800 for 65-year-old women. Kapadia et al.50
conducted an economic evaluation in which they explored using chlorhexidine cloths before total knee
arthroplasty and reported that for 1000 patients having total knee arthroplasty, a net saving of US$2.1M
occurred.29 This study assumed an estimated cost of US$130,000 per revision owing to infection, with
22 patients in a cohort of 1000 without use of the cloth becoming infected and six infections in the cohort
using the cloth. Two studies estimated revision costs for infected prosthetics: for infected hip arthroplasties,
estimated costs were £22,00051 and for infected knees, estimated costs were £30,000.52 These costs
included the revision surgery and subsequent inpatient stay.29 A 2013 review summarised the economic
literature in the treatment of periprosthetic joint infections, looking at prevention, treatment and surgical
options.53 Unlike the OVIVA trial, the treatment costs included the surgical costs of revision based on an
estimated average cost of US$50,000 to US$60,000 per patient with an infected total hip arthroplasty.48
None of these studies compared treatment costs of IV with PO antibiotics. The OVIVA trial estimated
non-surgical costs over the year to be £13,274 for those treated with IV antibiotics and £10,534 for those
treated with PO antibiotics.
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After imputation of missing values for resource use and health outcomes (QALYs), results remained
consistent with those obtained from complete-case analysis. QALYs reflect the primary outcome of
non-inferiority. Results from sensitivity analyses were also consistent with the complete-case and
imputation results.
Strengths
The OVIVA trial was pragmatic in that it was fully embedded into usual care and, as far as possible,
reflected standard practice in all respects other than randomisation of treatment strategy and data
collection. No additional diagnostic investigations, trial-specific clinic visits or blood tests were required of
the participants. This had the advantage of reducing the influence of possible differential observer effects
by treatment arm.
The OVIVA trial was a large trial and clinically evaluable primary end-point data were available for
1015 participants representing 96.3% of those randomised. This was well within the 10% allowance in
the sample size calculation for loss to follow-up.
Of the 39 participants lost to follow-up, only 14 (seven in each arm) withdrew consent to further involvement
with the trial. This suggests that the study design and patient pathway were generally acceptable.
The primary end point was hard in that it was predefined by clinically relevant criteria as used in daily
practice. When these criteria were not clearly fulfilled, a blinded end-point committee assessed potential
treatment failures from clinical records redacted for personal identifiers and for any indication of the
randomisation arm. The latter included redaction for all specifically named antibiotics, any reference to
IV lines and any reference to line complications, side effects and use of MEMS containers.
Recruitment criteria were highly inclusive. The hypothesis behind the trail was based strictly on the
pharmacokinetic principle that carefully selected PO antibiotics are as likely as IV antibiotics to achieve
sufficiently high concentrations to effect eradication of infection. Such a principle is unlikely to be influenced
by factors such as site of infection, retention of metal or causative organism. A more restrictive recruitment
strategy, for example selecting only participants with S. aureus infection or primary arthroplasty, would
have made the trial prohibitively long and would have limited the utility of the results. Although the inclusive
recruitment criteria resulted in an heterogeneous study population, we believe that the advantages of
generalisability outweigh the disadvantages of heterogeneity.
Weaknesses
The OVIVA trial was an open-label study. The decision to use this design was based on the two principles.
First, exposure of patients to a placebo IV therapy for a period of up to 6 weeks would have posed
unnecessary risks associated with the use of an intravascular access device and would, therefore, have
been unethical. Second, owing to the number of different antibiotics required to provide optimal care
for all patients randomised, it was not feasible to provide a matched placebo in every case. Although an
open-label design leaves the trial open to bias, the primary end points were determined according to
predefined criteria and an independent committee that was blinded to treatment allocation. This was
achieved through redaction from case notes of any information that might have betrayed the treatment
allocation (e.g. reference to IV access, OPAT, drug names, therapeutic drug monitoring). Primary end
points were defined by objective clinical and microbiological criteria, assessment of which required
attendance at, or admission to, hospital. Therefore, they were hard end points, the interpretation of
which was unlikely to have been influenced by treatment allocation or other confounding factors.
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The OVIVA trial was designed as a pragmatic trial that relied on routine care records as the primary source
of data. There were no research-specific clinic visits and no research-specific investigations. When possible,
and provided that the timings were commensurate with follow-up requirements of the trial, follow-up data
were collected through direct patient contact at their routine clinical reviews. When this was not possible,
the protocol allowed for telephone follow-up with the patient and the GP. Although primary end-point
data were available for all except 39 participants, it is possible that some potential treatment failures were
not identified. Although we think this unlikely, there is no reason to believe that unidentified losses
influenced one arm more than the other.
Eligibility for recruitment to the trial was based on clinical criteria rather than diagnostic laboratory results.
There are several reasons why we did not include histological or microbiological results as part of the
inclusion criteria. First, approximately 15% of bone and joint infections diagnosed clinically are not
confirmed microbiologically, for example, as a result of prior exposure to antibiotics or sampling error.54
Nonetheless, such patients are commonly treated for infection diagnosed on clinical criteria alone. Second,
the results of laboratory tests, particularly the histology results, are not always available within 7 days of
sampling; had we relied on laboratory results as part of the inclusion criteria, many patients would have
had to be excluded from this trial on account of this delay. Third, the pragmatic design of this trial gave
due autonomy over clinical management to the surgeon or physician responsible for the patient. If,
according to a research definition, infection was deemed not present, the trial could potentially have
undermined a clinician’s decision to treat an infection based on clinical criteria alone. Finally, in order to
account for the possibility that uninfected patients were included, every case that failed to meet a strict
prospective definition of infection at baseline was reviewed by an independent committee for a consensus
decision on their infection status at the time of recruitment.
There are three circumstances in which an apparent deviation from the allocated treatment arm might
have arisen.
First, participants were permitted IV therapy for up to 7 days following the start of planned curative
therapy, regardless of their randomised strategy (in most instances, the ‘start of planned curative therapy’
was the date of definitive surgical intervention). The rationale for this was to allow patients to recover from
the effects of anaesthesia before starting PO therapy and to allow sufficient time for microbiological results
to inform the optimal choice of antimicrobial agent. The availability of microbiological results was not a
requirement prior to randomisation but, because standard practice usually includes initial broad-spectrum
empiric IV antibiotics while waiting for microbiology results, we felt that a requirement for immediate
postoperative use of PO therapy might undermine clinical decision-making. Furthermore, operative
findings were an important component of eligibility and, as a result, most patients were randomised in
the postoperative period.
Second, for participants randomised to IV therapy, the use of adjunctive PO agents was permitted. This
may at first seem counterintuitive in a study that aimed to compare IV with PO therapy, but is based on
common practice outside the context of the trial. Examples include PO rifampicin, which is routinely used
alongside IV therapy in the management of biofilm-associated staphylococcal disease and metronidazole,
which is commonly used in polymicrobial osteomyelitis. To exclude patients allocated to the IV arm but
who require adjunctive PO therapy would likely incur a bias in favour of PO therapy.
Third, participants randomised to the PO arm were allowed up to 5 days of IV therapy to allow for
treatment of intercurrent illness or for short periods when, for unrelated reasons, PO therapy was not
appropriate. It was not designed to be used as a rescue treatment for the bone infection under therapy
and the protocol made this very clear. To withdraw participants on the grounds that they had an unrelated
concomitant illness which, in the opinion of a physician independent of the trial, required IV therapy would
have been considered unethical or discriminatory by some readers. Given that all patients had to have
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been prescribed at least 6 weeks of therapy for the incident bone infection, we believe that a short course
of IV therapy in a small minority of patients is unlikely significantly to have influenced the results. To ensure
transparency around both of these circumstances, all antibiotic use (including dose, route of administration
and duration) was recorded from the day of randomisation through to 1-year follow-up.
There was considerable variation in the number of participants recruited at each site, with over half being
recruited at just two centres. Both were tertiary referral specialist units, which consequently have high
volumes of orthopaedic surgery and its associated complications. Therefore, it is unsurprising that these
centres accrued a higher number of eligible patients than other centres. In addition, the single-centre pilot
study contributed 228 participants at one of these sites. The asymmetry of recruiting between sites is
unlikely to influence interpretation of the results and, in the 11 sites for which subgroup analysis was
possible, there was no evidence of an interaction between randomised treatment strategy and study site.
Follow-up in this trial was for 1 year with the facility to obtain final clinical review data up to 420 days.
The data points were made deliberately wide because the trial relied on routine clinic attendance to capture
end points and adverse events. Had we included trial-specific clinics at more tightly defined time points,
the trial may have been open to a greater influence of observer bias. Because follow-up was limited to
1 year, we cannot, of course, assume from our results that very late recurrences will be equally distributed
between those who were randomised to IV and PO therapy. However, there is no biologically plausible
reason to suggest otherwise and, given that the median total duration of therapy was around 11 weeks,
we believe that there was unlikely to be an advantage of following up participants for longer than 1 year.
There are some important caveats relating to antibiotic therapy in orthopaedic surgery and are detailed below.
First, the effective management of bone and joint infection is critically dependent on effective surgical
management. This may include careful and complete surgical debridement and excision, a meticulous
sampling framework to optimise diagnostics in the microbiology and histopathology laboratories, and early
vital soft tissue cover. Regardless of the route of administration, antibiotic therapy is likely to be ineffective
without appropriate and adequate surgical intervention. Researchers involved in this trial were self-selected
and are therefore likely to represent centres with surgical expertise specifically in the management of bone
and joint infection.
Second, the antimicrobial agents used in this trial were chosen by specialists in clinical infection, with
reference to bioavailability, tissue penetration and likely effectiveness against the known or presumed
pathogen. It cannot be assumed that an antibiotic will be effective based simply on the reported
susceptibility of the target organisms. This is particularly true for PO antibiotics for which a wide range of
agents is available and for which oral bioavailability and dose are critical for efficacy.
Third, because adherence to therapy is plausibly better with supervised IV therapy than with self-
administered PO therapy, participants in this trial were provided with written information explaining the
importance of adherence. It is critical that, if the findings of this study are used to support a change in
practice from routine use of IV to PO therapy, due consideration should be given to mechanisms to
promote adherence.
Fourth, patients managed with long courses of IV therapy, commonly through an OPAT service, are likely
to be more closely supervised than those on PO therapy during the first 6 weeks of treatment. Although the
trial did not demonstrate any difference in time to treatment failure between the two arms, it may be that,
because of their involvement in the trial, participants on PO therapy were more closely followed up than
they might have been outside the context of a trial. Extrapolation of the results into routine practice should
therefore take account of the need for adequate monitoring of patients after discharge.
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Comparison with previous studies
There have been a limited number of studies on this topic. A Cochrane review,15 which included data from
five trials involving a total of 180 patients with chronic osteomyelitis, demonstrated no benefit of IV over
PO antibiotic therapy, although the authors concluded that there was insufficient evidence to inform
clinical practice. We believe that the OVIVA trial provides sufficient support for these findings to allow
widespread adoption of PO therapy in this setting. Our results concur with The Infectious Diseases Society
of America guideline on the management of prosthetic joint infections,55 and a review by Fraimow,56
which suggest that the use of highly bioavailable PO agents may be an appropriate alternative to IV
therapy, provided that patient factors do not limit the drug’s pharmacokinetic properties.
Implications for practice
Patient pathways
There is a clear professional mandate to ensure patient-centred treatment, including, when possible,
limitation of hospital attendances, promotion of an independent life style and greater patient choice over
their own treatment.57 Such gains are less achievable with IV therapy than they are with PO therapy for
the following reasons:
l Use of IV therapy results in a delay in discharge from hospital, most commonly while awaiting insertion
of an IV access device and setting up OPAT. The median delay, quantified prospectively as part of the
OVIVA trial, was 3 days for patients managed with IV therapy.
l Clinic visits, although not quantified in this trial, would almost certainly have been more numerous
among those randomised to IV therapy than to PO therapy on account of therapeutic drug monitoring
and line checks/manipulation.
l Patients on IV therapy after discharge from hospital, unless self-administering, may find it inconvenient
to either arrange access in their own homes for a visiting nurse or to attend the hospital infusion centre
on a regular basis, usually daily. Furthermore, the presence of a line may restrict social and sporting
activities such as swimming, which patients may regard as important for their rehabilitation. Although
we did not specifically collect qualitative data to assess patient preference or satisfaction, we contributed
to a separate trial over the same period.58 This study suggested that, for prolonged IV therapy,
self-administration yielded significant cost savings, although patient preference was for home visits by
a specialist nurse. The study did not compare preference for IV therapy with preference for PO therapy.
l Conversations with our patient and public involvement (PPI) representatives revealed that a potential
further advantage of oral administration is the sense of control that patients feel over their own
treatment, particularly on account of the ease, familiarity and portability of tablets, that they would
not have had with IV therapy.
Patient safety
The use of IV lines pose risks that are not directly relevant to patients on PO therapy. For the purposes of
this trial, line complications were recorded as secondary end points (rather than SAEs) and included line
fracture or blockage, bleeding, thromboembolic events and line-related infection. Line-related infection
carries with it a crude mortality estimate of up to 25%.59 Around 10% of evaluable patients who were
randomised to IV therapy for the OVIVA study suffered a line-related complication. This figure is either
lower than or similar to other reports, although the populations involved are not directly comparable.60,61
Nonetheless, we believe that almost all of these complications could have been avoided in participants
managed with PO therapy.
Although we would not have expected line-related complications among those randomised to PO therapy,
five such instances were recorded. In four of these participants, the line was placed following early exit
from the randomised strategy (i.e. the participant was switched from PO to IV therapy during the
intervention period) and, in one participant, the line complication occurred after completion of the
intervention period.
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Cost
The acquisition cost of IV antibiotics is generally greater than that of PO therapy. In the OVIVA trial, the
mean total drug cost for those randomised to IV therapy was almost £800 greater than PO therapy.
IV therapy incurs additional costs relating to drug administration and prolonged hospitalisation. The mean
non-surgical treatment costs over the year for patients randomised to IV therapy was approximately £2700
greater than that of patients randomised to PO therapy. Extrapolation based on the most conservative
estimates used to inform the design of the OVIVA trial suggests a potential saving to the NHS of over
£30M if PO rather than IV therapy becomes the standard of care in the early treatment of bone and joint
infection across the UK.
Discussion with service users and PPI representatives suggested that the socioeconomic costs associated
with IV therapy represent a significant burden. Time absent from work, child care and travel to hospital
clinics were considered important. Additional hidden costs relating to delayed discharge, worry about
complications, lack of social engagement, work absence and effects on family/social environment were
all thought to be higher in those managed with IV therapy.
Antibiotic resistance
Antimicrobial stewardship activity has become a major priority in health care. PO therapy provides an
opportunity for a reduction in use of broad-spectrum antibiotics. The global threat of antimicrobial
resistance has been highlighted by the UK Chief Medical Officer as a very major risk to the NHS. Progress
in limiting the overall exposure to broad-spectrum antibiotics will reduce this threat and limit the risks of
health care associated infections such as C. difficile, methicillin-resistant S. aureus and carbapenemase-
producing Enterobacteriaceae. This is of particular relevance to the treatment of orthopaedic infections,
which commonly mandate an extended course of antibiotic therapy. Although not all PO antibiotics
are narrow spectrum, it is easier to select targeted therapy with PO agents than it is with IV agents.
The effective use of PO therapy in orthopaedic infection will help preserve the broad-spectrum IV antibiotic
use for serious infections, particularly when therapeutic options are limited.
Implications and suggestions for research
1. Given the advantages of PO over IV therapy discussed, the findings of this trial suggest that it would be
value to prospectively investigate its use in other conditions in which prolonged courses of IV therapy are
thought to be necessary for optimal outcome. These include bacteraemia, endocarditis and meningitis.
Although the incidence of these conditions is lower than that of bone and joint infection, there is still
considerable potential for patient benefit, cost reduction and improved antimicrobial stewardship.
2. To further support patient safety, cost improvement and antimicrobial stewardship, additional work
to define the optimal total duration of antibiotic therapy in bone and joint infection is necessary.
Currently, there is considerable variation between centres and between clinicians, which suggests that
there may be significant redundancy in antibiotic use. This almost certainly contributes to the risk of
emerging resistance to antimicrobials, an issue that is high on the agenda of the Department of Health
and Social Care and the medical community globally.
3. Effective antibiotic therapy requires the presence of therapeutic drug levels at the site of the infected
tissue. This depends on both bioavailability and tissue penetration. Optimising antibiotic choice will
require a programme of work that may include techniques such as microdialysis of tissue fluid at the
site of deep surgical infection.
4. There is currently growing interest in the literature around environmental factors that might influence
SSI rates. To limit the number of bone and joint infections arising as a complication of surgery, there is
considerable scope to investigate simple perioperative interventions that could reduce the risk of surgical
site infection in orthopaedics. Examples might include the influence of different patient-warming
technologies during surgery, the effect of preoperative transfusion and choice of postoperative dressings.
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Chapter 5 Conclusions
Despite its limitations, this trial is the largest study of its type addressing the question of route ofadministration of antibiotic therapy in bone and joint infection. Currently, the majority of centres that
manage complex bone and joint infections routinely use a prolonged course of IV antibiotics in the early
phase of therapy. The results of this trial suggest that this strategy has no advantage over PO therapy.
In addition, use of PO therapy will allow clinicians to mitigate the risks associated with IV access devices
normally used for long-term IV therapy. There was no significance difference in the incidence of C. difficile
diarrhoea or SAEs.
For patients, PO therapy provides an opportunity for earlier discharge from hospital, autonomy and
independence in managing their medications, and limitation of the risks associated with prolonged use
of IV access devices. These advantages have to be weighed against the risk of poor adherence with
unsupervised PO therapy. Although this did not appear to influence clinical outcome in the trial, adherence
monitoring during the trial may have influenced the behaviour of a subset of participants.
The demonstration of non-inferiority of PO therapy provides an important opportunity for antimicrobial
stewardship. Because the choice of PO agents is generally greater than that of IV agents, it seems likely
that the results of this trial will facilitate much greater capacity for individualisation of therapy, thereby
ensuring that the use of broad-spectrum agents can be better restricted to cases in which no alternatives
exist. It provides an important opportunity to support the global fight against emerging antimicrobial
resistance.
The results from the OVIVA trial could provide an opportunity for considerable cost savings. These arise
primarily from the shorter period of hospitalisation, the drug costs and the resources associated with
their administration. The health economic analyses in the OVIVA trial suggested that, on average, the
non-surgical treatment costs over 1 year for patients randomised to PO therapy were approximately
£2700 less than those of IV therapy.
Translation of the results from the OVIVA trial into clinical practice is likely to have important implications
for patients, health-care practitioners in the field of orthopaedic infection and the health economy.
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